Document:

Exhibit 10.19

 

 

 

February
23, 2015

 

PERSONAL
& CONFIDENTIAL

 

David Harrell

Chief Executive
Officer

OptimizeRx
Corp.

400 Water
Street, Suite 200

Rochester,
MI 48307

 

Dear Mr.
Harrell:

 

Merriman
Capital, Inc. ("Merriman") is pleased to act as a non-exclusive Capital Markets Advisor to OptimizeRx (the "Company").
The purpose of this relationship is to provide expertise to OptimizeRx management with regard to capital market interactions.
We will coordinate with OptimizeRx to develop and execute on a strategy to improve the overall positioning and visibility of the
Company as described below.

 

	 	1.	Services.
    In connection with this engagement, Merriman agrees to perform the following services on a "best efforts" basis:

 

	 	 	a.	Review
    the Company's current and historical financial information, capital structure and carry out customary due diligence;

 

	 	 	b.	Review
    any investor relations materials and/or public communications, including press releases, upon request of the Company and subject
    to any non-disclosure agreements between Merriman Capital and the Company;

 

	 	 	c.	Continue
    research coverage at the discretion of the analyst. There is no guarantee of research coverage, nor is there any guarantee
    that a favorable opinion will be rendered, even if the analyst chooses to cover the Company;

 

	 	 	d.	Provide
    access to Merriman clients and its sponsored conferences and events with the goal of increasing awareness of and marketing
    for the Company. This may include making introductions to qualified investors, one-on-one meetings, conference calls, road
    shows, spotlight events, and/or other traditional marketing activities;

 

	 	 	e.	Provide
    management with ongoing "advisory" recommendations and insights regarding capital market scenarios as needed and
    upon the request of management in areas where Merriman is deemed to have expertise;

 

	 	 	f.	Provide
    access to the Merriman Digital Capital Network (DCN) with data room and information on the Company on a non-deal basis, including
    outreach to the physicians who are registered on the DCN through Med Panel;

 

	 	 	g.	Assist
    in the development of strategic partnerships to escalate growth;

 

	 	 	h.	Assist
    in up-listing OPRX to a national market upon request, including the AMEX, NYSE or NASDAQ, with the understanding that the
    Company must first meet the requirements for up-listing to the chosen market.

 

 250
                                         MONTGOMERY STREET - 16TH Floor ■ San Francisco, CA 94104

1
(800) 909-7897 MAIN ■ (415) 248-5690 FAX

    	 

    	 

    

 

OptimizeRx Corp.

February
23, 2015 

Page
2

 

	 	2.	Remuneration.
    In conjunction with the execution of this Agreement, Merriman shall receive an initial payment in unregistered stock in
    the amount of 45,000 shares of OPRX. An additional payment in the equal amount of 45,000 unregistered shares shall be remitted
    to Merriman on or before August 15, 2015, subject to the terms of engagement detailed in Section (4) below. The company also
    agrees to file a registration statement for the initial shares within 30 days of filing its 2014 10K and agrees to file another
    registration statement within 30 days of issuing the second payment of OPRX shares. Any other services that the Company may
    require shall be covered separately under another agreement. Except as expressly set forth in this Agreement, these fees are
    NON-REFUNDABLE and only cover the Capital Markets Advisory Services described in Section (1) above.

 

	 	3.	Special
    Incentive Bonus. In the event that the Company successfully completes an up-listing to any of the national markets
    designated as the AMEX, NYSE, or NASDAQ Merriman shall earn a special incentive bonus of 60,000 unregistered OPRX shares.
    The Company agrees to issue these shares immediately upon the completion of the up-listing and file a registration statement
    covering this Special Incentive Bonus stock within 30 days of issuance, or concurrent with the registration of shares in Section
    (2) above, at the Company's discretion. It is also understood that these shares are to be granted expressly for the successful
    completion of the service described in Section 1(h) above and without regard to any of the other agreed services in Section
    1 (a)-(g).

 

	 	4.	Term
    of Engagement. Merriman representation is on a non-exclusive basis and will continue for a period of Twelve (12) months
    from the date of execution of this agreement. Merriman may terminate the relationship at any time upon thirty (30) days written
    notice to the Company, provided, however, that if such termination is without cause, Merriman shall return a portion of the
    fee received equal to the pro-rata portion of the term remaining. Termination may occur at the request of the Company with
    thirty days written notice with the understanding that all payments are non-refundable and there is no credit due to the Company.
    If the Company should request termination with at least 30 days written notice before the second payment is due on August
    15, 2015, the Company will not be required to make said payment and this agreement will be terminated without further obligation
    by either Merriman or the Company.

 

	 	5.	Scope
    of Engagement. Merriman has been engaged by the Company only in connection with the matters described in this letter
    agreement and for no other purpose. Merriman shall not be required to render any advice or reports in writing or to perform
    any other services outside of the scope of services described in Section (1). We have not made, and will assume no responsibility
    to make, any representation in connection with our engagement as to any legal matter.

 

	 	6.	Information
    Provided to Merriman. In connection with the engagement, the Company has agreed to furnish to Merriman, on a timely
    basis, all relevant information needed by Merriman to perform its services under the terms of this agreement. We do not assume
    any responsibility for the accuracy, completeness or fairness of the information and data supplied to us by the Company or
    its representatives. In addition, the Company acknowledges that we will assume without independent verification that all
    information supplied to us with respect to the Company will be true, correct and complete in all material respects.

 

 

250
MONTGOMERY STREET - 16TH Floor ■ San Francisco, CA 94104

1 (800) 909-7897 MAIN ■
(415) 248-5690 FAX

    	 

    	 

    

 OptimizeRx
Corp.

February
23, 2015 

Page
3

 

	 	7.	Indemnity
    and Contribution. The parties agree to the terms of Merriman's standard indemnification agreement, which is attached
    hereto as Appendix A and incorporated herein by reference. The provisions of this paragraph shall survive any termination
    of this agreement.

 

	 	8.	Other
    Merriman Activities. Merriman is a full service securities firm engaged in securities trading and brokerage activities,
    in addition to providing research, investment banking and financial advisory services. Nothing herein contained shall be construed
    to limit or restrict Merriman in conducting such business with respect to others, or in rendering any advice to others, except
    in matters relating to the Company's business that are deemed confidential by a separate written agreement.

 

	 	9.	Compliance
    with Applicable Law. In connection with this engagement, the Company and Merriman will comply with all applicable
    federal, state and foreign securities laws and other applicable laws and regulations.

 

	 	10.	Independent
    Contractor. Merriman is an independent contractor. Merriman shall have no liability as a result of this agreement
    and no authority to bind or act for the Company in any respect. It is understood that Merriman's responsibility to the Company
    is solely contractual in nature and that Merriman does not owe the Company, or any other party, any fiduciary duty as a result
    of its engagement.

 

	 	11.	Announcements.
    The Company grants Merriman Capital the right to make public announcements of this engagement and to place announcements
    in certain newspapers and/or to mail announcements to persons and firms selected by Merriman at our discretion, with all costs
    of such announcements to be borne by Merriman.

 

	 	12.	Governing
    Law and Venue. This agreement shall be governed by and construed under the laws of the State of California applicable
    to contracts made and to be performed entirely within the State of California. Any disputes shall be determined by recourse
    to the federal and state courts located binding arbitration in the City and County of San Francisco This clause shall not
    preclude parties from seeking provisional remedies in aid of arbitration from a court of appropriate jurisdiction. Each party
    will bear its own costs for litigation. The prevailing party in litigation arbitration shall be entitled to reasonable attorneys'
    fees. The provisions of this paragraph shall survive any termination of this agreement.

 

 

250
MONTGOMERY STREET - 16TH Floor ■ San Francisco, CA 94104

1 (800) 909-7897 MAIN ■ (415)
248-5690 FAX

    	 

    	 

    

 

OptimizeRx
Corp.

February
23, 2015

Page
4

 

	 	13.	General
    Provisions. The terms of this letter agreement will be valid unless modifications
are made in writing and signed by both parties hereto. Section headings used in this letter agreement are for convenience only,
are not a part of this letter agreement and will not be used in construing any of the terms hereof. This letter agreement constitutes
and embodies the entire understanding and agreement of the parties hereto relating to the subject matter hereof, and there are
no other agreements or understandings, written or oral, in effect between the parties relating to the subject matter hereof. No
representation, promise, inducement or statement of intention has been made by either of the parties hereto which is to be embodied
in this letter agreement, and none of the parties hereto shall be bound by or liable for any alleged representation, promise,
inducement or statement of intention, not so set forth herein. No provision of this letter agreement shall be construed in favor
of or against either of the parties hereto by reason of the extent to which either of the parties or its counsel participated
in the drafting hereof, if any provision of this letter agreement is held by a court of competent jurisdiction to be invalid,
illegal or unenforceable, the remaining provisions hereof shall in no way be affected and shall remain in full force and effect.
This letter agreement may be executed in any number of counterparts and by facsimile signature.

 

{REMAINDER
INTENTIONALLY LEFT BLANK}

 250
MONTGOMERY STREET - 16TH Floor ■ San Francisco, CA 94104

1 (800) 909-7897 MAIN ■ (415)
248-5690 FAX

    	 

    	 

    

 

OptimizeRx
Corp.

February
23, 2015

Page
5

 

If
the foregoing correctly sets forth your understanding of the agreement, please sign the enclosed copy of this letter and return
it to Merriman.

 

	 	Very truly yours, 
	 	 	 
	 	MERRIMAN CAPITAL, INC.
	 	 	 
	 	By:	/s/ Jon Merriman
	 	 	Jon Merriman
	 	 	Chief Executive Officer

 

The
undersigned hereby accepts, agrees to and becomes party to the foregoing letter agreement, effective as of the date first written
above.

 

	OPTIMIZERX
    CORPORATION	 
	 		 
	By:	/s/ David
    Harrell	 
	 	 	 
	Name:	David Harrell	 
	 	 	 
	Title:	CEO	 
	 	 	 
	Effective
    Date:	2/27/15	 

 

 

250
MONTGOMERY STREET - 16TH Floor ■ San Francisco, CA 94104

1 (800) 909-7897 MAIN ■
(415) 248-5690 FAX

    	 

    	 

    

 

OptimizeRx Corp.

February
23, 2015

Page
6

 

APPENDIX
A — INDEMNIFICATION AGREEMENT

 

The
Company agrees to indemnify and hold harmless Merriman and its officers, directors, employees, consultants, attorneys, agents,
affiliates, parent company and controlling persons (within the meaning of Section 15 of the Securities Act of 1933, as amended,
or Section 20 of the Securities Exchange Act of 1934, as amended) (Merriman and each such other persons are collectively and individually
referred to below as an "Indemnified Party") from and against any and all loss, claim, damage, liability and expense
whatsoever, as incurred, including, without limitation, reasonable costs of any investigation, legal and other fees and expenses
incurred in connection with, and any amounts paid in settlement of, any action, suit or proceeding or any claim asserted, to which
the Indemnified Party may become subject under any applicable federal or state law (whether in tort, contract or on any other
basis) or otherwise, (i) arising out of or based upon any untrue statement or alleged untrue statement of a material fact contained
in any written or oral communication provided by or on behalf of the Company to any actual or prospective purchaser of the securities
or arising out of or based upon the omission or alleged omission to state therein a material fact required to be stated therein
or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading
or (ii) related to the performance by the Indemnified Party of the services contemplated by this letter agreement (including,
without limitation, the offer and sale of the securities) and will reimburse the Indemnified Party for all expenses (including
legal fees and expenses) in connection with the investigation of, preparation for or defense of any pending or threatened claim
or any action or proceeding arising therefrom, whether or not the Indemnified Party is a party and whether or not such claim,
action or proceeding is initiated or brought by the Company. The Company will not be liable under clause (ii) of the foregoing
indemnification provision to the extent that any loss, claim, damage, liability or expense is found in a final judgment by a court
or arbitrator, not subject to appeal or further appeal, to have resulted directly from the Indemnified Party's willful misconduct
or gross negligence. The Company also agrees that the Indemnified Party shall have no liability (whether direct or indirect, in
contract, tort or otherwise) to the Company related to, or arising out of, the engagement of the Indemnified Party pursuant to,
or the performance by the Indemnified Party of the services contemplated by, this letter agreement except to the extent that any
loss, claim, damage, liability or expense is found in a final judgment by a court or arbitrator, not subject to appeal or further
appeal, to have resulted directly from the Indemnified Party's willful misconduct or gross negligence.

 

 

250
MONTGOMERY STREET - 16TH Floor ■ San Francisco, CA 94104

1 (800) 909-7897 MAIN ■
(415) 248-5690 FAX

    	 

    	 

    

 

OptimizeRx
Corp.

February
23, 2015

Page
7

 

If
the indemnity provided above shall be unenforceable or unavailable for any reason whatsoever, the Company, its successors and
assigns, and the Indemnified Party shall contribute to all such losses, claims, damages, liabilities and expenses (including,
without limitation, all costs of any investigation, legal or other fees and expenses incurred in connection with, and any amounts
paid in settlement of, any action, suit or proceeding or any claim asserted) (i) in such proportion as is appropriate to reflect
the relative benefits received by the Company and Merriman under the terms of this letter agreement or (ii) if the allocation
provided for by clause

 

(i)
of this sentence is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative
benefits referred to in clause (i), but also the relative fault of the Company and Merriman in connection with the matter(s)
as to which contribution is to be made. The relative benefits received by the Company and Merriman shall be deemed to be in
the same proportion as the fee the Company actually pays to Merriman bears to the total value of the consideration
paid or to be paid to the Company. The relative fault of the Company and Merriman shall be determined by reference to, among
other things, whether any untrue or alleged untrue statement of material fact or omission or alleged omission to state a
material fact relates to information supplied by the Company or by Merriman and the Company's and Merriman's relative intent,
knowledge, access to information and opportunity to correct. The Company and Merriman agree that it would not be just or
equitable if contribution pursuant to this paragraph were determined by pro rata allocation or by any other method of
allocation which does not take into account these equitable considerations. Notwithstanding the foregoing, to the extent
permitted by law, in no event shall the Indemnified Party's share of such losses, claims, damages, liabilities and expenses
exceed, in the aggregate, the fee actually paid to the Indemnified Party by the Company. The Company further agrees that,
without Merriman's prior written consent, which consent will not be unreasonably withheld, it will not enter into any
settlement of a lawsuit, claim or other proceeding arising out of the transactions contemplated by this agreement unless such
settlement includes an explicit and unconditional release from the party bringing such lawsuit, claim or other proceeding of
all such lawsuits, claims, or other proceedings against the Indemnified Parties.

 

 

250
MONTGOMERY STREET - 16TH Floor ■ San Francisco, CA 94104

1 (800) 909-7897 MAIN ■
(415) 248-5690 FAX

    	 

    	 

    

OptimizeRx
Corp.

February
23, 2015

Page
8

 

The
Indemnified Party will give prompt written notice to the Company of any claim for which it seeks indemnification hereunder, but
the omission to so notify the Company will not relieve the Company from any liability which it may otherwise have hereunder except
to the extent that the Company is damaged or prejudiced by such omission or from any liability it may have other than under this
Appendix A. The Company shall have the right to assume the defense of any claim, lawsuit or action (collectively an "action")
for which the Indemnified Party seeks indemnification hereunder, subject to the provisions stated herein with counsel reasonably
satisfactory to the Indemnified Party. After notice from the Company to the Indemnified Party of its election to assume the defense
thereof, and so long as the Company performs its obligations pursuant to such election, the Company will not be liable to the
Indemnified Party for any legal or other expenses subsequently incurred by the Indemnified Party in connection with the defense
thereof other than reasonable costs of investigation. The Indemnified Party shall have the right to employ separate counsel in
any such action and to participate in the defense thereof at its own expense; provided, however, that the reasonable fees and
expenses of such counsel shall be at the expense of the Company if (1) the employment thereof has been specifically authorized
by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ
counsel or (iii) the named parties to any such action (including any impleaded parties) include both the Indemnified Party and
the Company and the Indemnified Party shall have reasonably concluded, based on advice of counsel, that there may be legal defenses
available to the Indemnified Party which are different from, or in conflict with, any legal defenses which may be available to
the Company (in which event the Company shall not have the right to assume the defense of such action on behalf of the Indemnified
Party, it being understood, however, that the Company shall not be liable for the reasonable fees and expenses of more than one
separate firm of attorneys for all Indemnified Parties in each jurisdiction in which counsel is needed). Despite the foregoing,
the Indemnified Party shall not settle any claim without the prior written approval of the Company, which approval shall not be
unreasonably withheld, so long as the Company is not in material breach of this Appendix A. Also, each Indemnified Party shall
make reasonable efforts to mitigate its losses and liabilities. In addition to the Company's other obligations hereunder and without
limitation, the Company agrees to pay monthly, upon receipt of itemized statements therefor, all reasonable fees and expenses
of counsel incurred by an Indemnified Party in defending any claim of the type set forth in the preceding paragraphs or in producing
documents, assisting in answering any interrogatories, giving any deposition testimony or otherwise becoming involved in any action
or response to any claim relating to the engagement referred to herein, or any of the matters enumerated in the preceding paragraphs,
whether or not any claim is made against an Indemnified Party or an Indemnified Party is named as a party to any such action.

 

 

250
MONTGOMERY STREET - 16TH Floor ■ San Francisco, CA 94104

1 (800) 909-7897 MAIN ■
(415) 248-5690 FAXExhibit 10.1

 

 

 

CREDIT AGREEMENT AND GUARANTY

 

dated as of May 29, 2015

 

by and among

 

ALLIQUA BIOMEDICAL, INC.,

as the Borrower,

 

THE GUARANTORS PARTY HERETO,

 

and

 

PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP,

as the Lender

 

 

 

    	 

    	 	 	 

    

 

Table
of Contents

 

	 	 	 	Page
	 	 	 	 
	Article I	DEFINITIONS AND ACCOUNTING TERMS	1
	 	 	 	 
	 	Section 1.1	Defined Terms	1
	 	 	 	 
	 	Section 1.2	Use of Defined Terms	18
	 	 	 	 
	 	Section 1.3	Cross-References	18
	 	 	 	 
	 	Section 1.4	Accounting and Financial Determinations	19
	 	 	 	 
	Article II	COMMITMENT AND BORROWING PROCEDURES	19
	 	 	 	 
	 	Section 2.1	Commitment	19
	 	 	 	 
	 	Section 2.2	Borrowing Procedures	19
	 	 	 	 
	 	Section 2.3	Funding	19
	 	 	 	 
	 	Section 2.4	Reduction of the Commitment Amounts	19
	 	 	 	 
	Article III	REPAYMENTS, PREPAYMENTS, INTEREST AND FEES	19
	 	 	 	 
	 	Section 3.1	Repayments and Prepayments; Application	19
	 	 	 	 
	 	Section 3.2	Repayments and Prepayments	19
	 	 	 	 
	 	Section 3.3	Application	21
	 	 	 	 
	 	Section 3.4	Reinvestment of Certain Proceeds	21
	 	 	 	 
	 	Section 3.5	Interest Rate	21
	 	 	 	 
	 	Section 3.6	Default Rate	21
	 	 	 	 
	 	Section 3.7	Payment Dates	21
	 	 	 	 
	 	Section 3.8	Exit Fee	22
	 	 	 	 
	 	Section 3.9	Fees	22
	 	 	 	 
	Article IV	LIBO RATE AND OTHER PROVISIONS	22
	 	 	 	 
	 	Section 4.1	Increased Costs, Etc	22
	 	 	 	 
	 	Section 4.2	Increased Capital Costs	23
	 	 	 	 
	 	Section 4.3	Taxes	23
	 	 	 	 
	 	Section 4.4	Payments, Computations; Proceeds of Collateral, Etc	26
	 	 	 	 
	 	Section 4.5	Setoff	27
	 	 	 	 
	 	Section 4.6	LIBO Rate Not Determinable	27
	 	 	 	 
	Article V	CONDITIONS TO LOAN	27
	 	 	 	 
	 	Section 5.1	Loan	27
	 	 	 	 
	Article VI	REPRESENTATIONS AND WARRANTIES	31

 

    	-i-

    	 	 	 

    

 

Table
of Contents

(continued)

 

	 	 	 	Page
	 	 	 	 
	 	Section 6.1	Organization, Etc	31
	 	 	 	 
	 	Section 6.2	Due Authorization, Non-Contravention, Etc	31
	 	 	 	 
	 	Section 6.3	Government Approval, Regulation, Etc	32
	 	 	 	 
	 	Section 6.4	Validity, Etc	32
	 	 	 	 
	 	Section 6.5	Financial Information	32
	 	 	 	 
	 	Section 6.6	No Material Adverse Change	32
	 	 	 	 
	 	Section 6.7	Litigation, Labor Matters and Environmental Matters	32
	 	 	 	 
	 	Section 6.8	Subsidiaries	33
	 	 	 	 
	 	Section 6.9	Ownership of Properties	33
	 	 	 	 
	 	Section 6.10	Taxes	33
	 	 	 	 
	 	Section 6.11	Pension Plans, Etc	33
	 	 	 	 
	 	Section 6.12	Accuracy of Information	33
	 	 	 	 
	 	Section 6.13	Regulations U and X	34
	 	 	 	 
	 	Section 6.14	Solvency	34
	 	 	 	 
	 	Section 6.15	Intellectual Property	34
	 	 	 	 
	 	Section 6.16	Material Agreements	35
	 	 	 	 
	 	Section 6.17	Permits	35
	 	 	 	 
	 	Section 6.18	Regulatory Matters	36
	 	 	 	 
	 	Section 6.19	Transactions with Affiliates	38
	 	 	 	 
	 	Section 6.20	Investment Company Act	38
	 	 	 	 
	 	Section 6.21	OFAC	38
	 	 	 	 
	 	Section 6.22	Anti-Corruption	38
	 	 	 	 
	 	Section 6.23	Deposit and Disbursement Accounts	38
	 	 	 	 
	 	Section 6.24	Registration Rights	38
	 	 	 	 
	 	Section 6.25	Use of Proceeds	39
	 	 	 	 
	Article VII	AFFIRMATIVE COVENANTS	39
	 	 	 	 
	 	Section 7.1	Financial Information, Reports, Notices, Etc	39
	 	 	 	 
	 	Section 7.2	Maintenance of Existence; Compliance with Contracts, Laws, Etc	41
	 	 	 	 
	 	Section 7.3	Maintenance of Properties	41

 

    	-ii-

    	 	 	 

    

 

Table
of Contents

(continued)

 

	 	 	 	Page
	 	 	 	 
	 	Section 7.4	Insurance	41
	 	 	 	 
	 	Section 7.5	Books and Records	42
	 	 	 	 
	 	Section 7.6	Environmental Law Covenant	42
	 	 	 	 
	 	Section 7.7	Use of Proceeds	42
	 	 	 	 
	 	Section 7.8	Future Guarantors, Security, Etc	42
	 	 	 	 
	 	Section 7.9	Obtaining of Permits, Etc	43
	 	 	 	 
	 	Section 7.10	Product Licenses	43
	 	 	 	 
	 	Section 7.11	Maintenance of Regulatory Authorizations, Contracts, Intellectual Property, Etc	43
	 	 	 	 
	 	Section 7.12	Restriction of Amendments to Certain Documents	44
	 	 	 	 
	 	Section 7.13	Cash Management	44
	 	 	 	 
	 	Section 7.14	Modification of Organic Documents	45
	 	 	 	 
	 	Section 7.15	Inconsistent Agreements	45
	 	 	 	 
	Article VIII	NEGATIVE COVENANTS	45
	 	 	 	 
	 	Section 8.1	Business Activities	45
	 	 	 	 
	 	Section 8.2	Indebtedness	45
	 	 	 	 
	 	Section 8.3	Liens	46
	 	 	 	 
	 	Section 8.4	Financial Covenants	47
	 	 	 	 
	 	Section 8.5	Investments	47
	 	 	 	 
	 	Section 8.6	Restricted Payments, Etc	48
	 	 	 	 
	 	Section 8.7	Issuance of Capital Securities	48
	 	 	 	 
	 	Section 8.8	Consolidation, Merger; Permitted Acquisitions, Etc	48
	 	 	 	 
	 	Section 8.9	Permitted Dispositions	49
	 	 	 	 
	 	Section 8.10	Modification of Certain Agreements	49
	 	 	 	 
	 	Section 8.11	Transactions with Affiliates	49
	 	 	 	 
	 	Section 8.12	Restrictive Agreements, Etc	49
	 	 	 	 
	 	Section 8.13	Sale and Leaseback	49
	 	 	 	 
	 	Section 8.14	Product Sales	49
	 	 	 	 
	 	Section 8.15	Outbound Licenses	49
	 	 	 	 
	 	Section 8.16	Inbound Licenses	50

 

    	-iii-

    	 	 	 

    

 

Table
of Contents

(continued)

 

	 	 	 	Page
	 	 	 	 
	 	Section 8.17	Change in Name, Location, Executive Office, or Executive Management; Change in Fiscal Year	50
	 	 	 	 
	Article IX	EVENTS OF DEFAULT	50
	 	 	 	 
	 	Section 9.1	Listing of Events of Default	50
	 	 	 	 
	 	Section 9.2	Action if Bankruptcy	53
	 	 	 	 
	 	Section 9.3	Action if Other Event of Default	53
	 	 	 	 
	Article X	GUARANTY	 	53
	 	 	 	 
	 	Section 10.1	Guaranty	53
	 	 	 	 
	 	Section 10.2	Waivers	54
	 	 	 	 
	 	Section 10.3	Benefit of Guaranty	54
	 	 	 	 
	 	Section 10.4	Subordination of Subrogation, Etc	54
	 	 	 	 
	 	Section 10.5	Election of Remedies	55
	 	 	 	 
	 	Section 10.6	Limitation	55
	 	 	 	 
	 	Section 10.7	Liability Cumulative	55
	 	 	 	 
	Article XI	MISCELLANEOUS PROVISIONS	55
	 	 	 	 
	 	Section 11.1	Waivers, Amendments, Etc	55
	 	 	 	 
	 	Section 11.2	Notices; Time	56
	 	 	 	 
	 	Section 11.3	Payment of Costs and Expenses	56
	 	 	 	 
	 	Section 11.4	Indemnification	57
	 	 	 	 
	 	Section 11.5	Survival	57
	 	 	 	 
	 	Section 11.6	Severability	57
	 	 	 	 
	 	Section 11.7	Headings	58
	 	 	 	 
	 	Section 11.8	Execution in Counterparts, Effectiveness, Etc	58
	 	 	 	 
	 	Section 11.9	Governing Law; Entire Agreement	58
	 	 	 	 
	 	Section 11.10	Successors and Assigns	58
	 	 	 	 
	 	Section 11.11	Other Transactions	59
	 	 	 	 
	 	Section 11.12	Forum Selection and Consent to Jurisdiction	59
	 	 	 	 
	 	Section 11.13	Waiver of Jury Trial	59

 

    	-iv-

    	 	 	 

    

 

Table
of Contents

(continued)

 

	 	 	Page
	 	 	 
	SCHEDULES: 	 	 
	 	 	 
	Schedule 1.1(a)	 	Key Permits
	Schedule 6.7(a)	 	Litigation
	Schedule 6.8	 	Existing Subsidiaries
	Schedule 6.11	 	Pension Plans
	Schedule 6.15(a)	 	Intellectual Property
	Schedule 6.16(a)	 	Material Agreements
	Schedule 6.16(b)	 	Excluded Material Agreements 
	Schedule 6.18(a)	 	Regulatory Matters
	Schedule 6.19	 	Transactions with Affiliates
	Schedule 6.23	 	Deposit and Disbursement Accounts
	Schedule 6.24	 	Registration Rights
	Schedule 8.2(c)	 	Existing Indebtedness
	Schedule 8.3(b)	 	Existing Liens
	Schedule 8.5(a)	 	Investments
	Schedule 8.7	 	Issuance of Capital Securities
	Schedule 11.2	 	Notice Information
	 	 	 
	EXHIBITS:	 	 
	 	 	 
	Exhibit A	-	Form of Note
	Exhibit B	-	Form of Loan Request
	Exhibit C	-	Form of Compliance Certificate
	Exhibit D	-	Form of Pledge and Security Agreement
	Exhibit E	-	Form of Copyright Security Agreement
	Exhibit F	-	Form of Patent Security Agreement
	Exhibit G	-	Form of Trademark Security Agreement
	Exhibit H	-	Form of Warrant 
	Exhibit I-1	-	Form of U.S. Tax Compliance Certificate
	Exhibit I-2	-	Form of U.S. Tax Compliance Certificate
	Exhibit I-3	-	Form of U.S. Tax Compliance Certificate
	Exhibit I-4	-	Form of U.S. Tax Compliance Certificate
	Exhibit J	-	Form of Solvency Certificate
	Exhibit K	-	Form of Subordination Agreement

 

    	-v-

    	 	 	 

    

 

CREDIT AGREEMENT AND GUARANTY

 

THIS CREDIT AGREEMENT AND GUARANTY dated
as of May 29, 2015 (as amended, supplemented or otherwise modified from time to time, this “Agreement”), is
by and among ALLIQUA BIOMEDICAL, INC., a Delaware corporation (the “Borrower”), each Guarantor (as defined below)
party hereto and PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP (together with its Affiliates, successors, permitted transferees and
permitted assignees, the “Lender”).

 

WITNESSETH:

 

WHEREAS, the Borrower has requested that
the Lender provide a senior term loan facility to the Borrower in an aggregate principal amount of $15,500,000 on the Closing Date;
and

 

WHEREAS, the Lender is willing, on the terms
and subject to the conditions hereinafter set forth, to extend the Commitment and make the Loan to the Borrower.

 

NOW, THEREFORE, the parties hereto agree
as follows:

 

Article
I

DEFINITIONS
AND ACCOUNTING TERMS

 

Section
1.1 Defined Terms. The following terms (whether or not underscored) when used in this Agreement, including its preamble
and recitals, shall, except where the context otherwise requires, have the following meanings (such meanings to be equally applicable
to the singular and plural forms thereof):

 

“510(k)” is defined within
the definition of “Device Clearance Application”.

 

“Affiliate” of any Person
means any other Person which, directly or indirectly, controls, is controlled by or is under common control with such Person. “Control”
(and its correlatives) by any Person means the power of such Person, directly or indirectly, (i) to vote 10% or more of the Capital
Securities (on a fully diluted basis) of another Person which Capital Securities have ordinary voting power for the election of
directors, managing members or general partners (as applicable), or (ii) to direct or cause the direction of the management and
policies of such other Person (whether by contract or otherwise).

 

“Agreement” is defined
in the preamble.

 

“Applicable Margin” means
9.75%, as such percentage may be increased pursuant to Section 3.6.

 

“Ancillary Documents”
has the meaning provided in the Merger Agreement.

 

“Authorized Officer”
means, relative to each Loan Party, those of its officers, general partners or managing members (as applicable) whose signatures
and incumbency shall have been certified to the Lender pursuant to Section 5.1.1.

 

    	 

    	 	 	 

    

 

“BLA” means (i)
(x) a biologics license application (as defined in the FD&C Act) to introduce, or deliver for introduction, a biologic
product, including vaccines into commerce in the U.S., or any successor application or procedure and (y) any similar application
or functional equivalent relating to biologics licensing applicable to or required by any country, jurisdiction or Governmental
Authority other than the U.S. and (ii) all supplements and amendments that may be filed with respect to the foregoing.

 

“Borrower” is defined
in the preamble.

 

“Borrower Material Contract”
means any material contract of any Loan Party required to be filed on a Current Report on Form 8-K, a Quarterly Report on Form
10-Q, or an Annual Report on Form 10-K, in each case pursuant to Item 601(a) and Item 601(b)(10) of Regulation S-K promulgated
by the Securities and Exchange Commission.

 

“Business Day” means
any day which is neither a Saturday nor Sunday nor a legal holiday on which banks are authorized or required to be closed in New York,
New York.

 

“Calculation Date” is
defined in Section 8.4(a).

 

“Capital Securities”
means, with respect to any Person, all shares of, interests or participations in, or other equivalents in respect of (in each case
however designated, whether voting or non-voting), such Person’s capital stock, whether now outstanding or issued after the
Closing Date.

 

“Capitalized Lease Liabilities”
means, with respect to any Person, all monetary obligations of such Person and its Subsidiaries under any leasing or similar arrangement
which have been (or, in accordance with GAAP, should be) classified as capitalized leases, and for purposes of each Loan Document
the amount of such obligations shall be the capitalized amount thereof, determined in accordance with GAAP, and the stated maturity
thereof shall be the date of the last payment of rent or any other amount due under such lease prior to the first date upon which
such lease may be terminated by the lessee without payment of a premium or a penalty.

 

“Cash Equivalent Investment”
means, at any time:

 

(a) any direct obligation of (or
unconditionally guaranteed by) the United States or a state thereof (or any agency or political subdivision thereof, to the extent
such obligations are supported by the full faith and credit of the United States or a state thereof) maturing not more than one
year after such time;

 

(b) commercial paper maturing
not more than 270 days from the date of issue, which is issued by a corporation (other than an Affiliate of the Borrower or any
of its Subsidiaries) organized under the laws of any state of the United States or of the District of Columbia and rated A-1 or
higher by S&P or P-1 or higher by Moody’s;

 

(c) any certificate of deposit,
time deposit or bankers acceptance, maturing not more than one year after its date of issuance, which is issued by any bank organized
under the laws of the United States (or any state thereof) and which has (x) a credit rating of A2 or higher from Moody’s
or A or higher from S&P and (y) a combined capital and surplus greater than $1,000,000,000; or

 

    	- 2 -

    	 	 	 

    

 

(d) investments in money market
funds substantially all of whose assets are comprised of securities of the types described in clauses (a) through (c) above.

 

“Celgene License Agreement”
means the License, Marketing and Development Agreement dated as of November 2013, between the Borrower and Anthrogenesis Corporation,
d/b/a Celgene Cellular Therapeutics, as amended or otherwise modified.

 

“Celleration” means Celleration,
Inc., a Delaware corporation.

 

“Celleration Material Contract”
means any Material Contract as that term is defined in the Merger Agreement.

 

“Change in Control” means
and shall be deemed to have occurred if (i) any “person” or “group” (within the meaning of Rule 13d-5
of the Exchange Act as in effect on the date hereof) shall own, directly or indirectly, beneficially or of record, determined on
a fully diluted basis, more than 30% of the Voting Securities of the Borrower, (ii) a majority of the seats (other than vacant
seats) on the board of directors (or equivalent) of the Borrower shall at any time be occupied by persons who were neither (x) nominated
by the board of directors of the Borrower nor (y) appointed by directors so nominated, (iii) the Borrower shall cease
to directly own, beneficially and of record, 100% of the issued and outstanding Capital Securities of its Subsidiaries or (iv)
the sale, lease, transfer, conveyance or other disposition, in one or more related transactions, of properties or assets of the
Loan Parties having an aggregate value in excess of 30% of all properties and assets of such Persons determined, as of any relevant
time, by reference to the Borrower’s most recent audited, consolidated balance sheet.

 

“Change in Law” means
the occurrence, after the date of this Agreement, of any of the following: (i) the adoption or taking effect of any law, rule,
regulation or treaty, (ii) any change in any law, rule, regulation or treaty or in the administration, interpretation, implementation
or application thereof by any Governmental Authority or (iii) the making or issuance of any request, rule, guideline or directive
(whether or not having the force of law) by any Governmental Authority; provided that, notwithstanding anything herein to
the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives
thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for
International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States
or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a “Change in Law”,
regardless of the date enacted, adopted or issued.

 

“Closing Date” means
the date of the making of the Loan hereunder, which shall coincide with the “Closing Date” as defined in the Merger
Agreement.

 

“Closing Date Certificate”
is defined in Section 5.1.2.

 

    	- 3 -

    	 	 	 

    

 

“Closing Date Material Adverse
Effect” means any event, occurrence, fact, condition, circumstance or change that is, or could reasonably be expected
to become, individually or in the aggregate, materially adverse to the business, results of operations or financial condition of
(x) the Borrower and its Subsidiaries taken as a whole or (y) Celleration and its Subsidiaries taken as a whole, as the case may
be, but shall not include any event, occurrence, fact, condition or change, directly or indirectly, arising out of or attributable
to: (i) general economic or political conditions; (ii) conditions generally affecting the industries in which the Borrower, Celleration
or any of its respective Subsidiaries, as the case may be, operates; (iii) any changes in financial or securities markets in general;
(iv) acts of war (whether or not declared), armed hostilities or terrorism, or the escalation or worsening thereof; (v) any action
expressly required by the Merger Agreement (other than pursuant to Section 3.03 and Section 5.08 thereof), the Commitment
Letter, and/or the Loan Documents; (vi) any changes in applicable laws or accounting rules, including GAAP in the United States;
or (viii) any decline in the NASDAQ listed price for any Loan Party’s equity securities following the announcement of the
Merger Transaction; provided further, however, that any event, occurrence, fact, condition or change referred
to in clauses (i) through (iv) and/or (vi) immediately above shall be taken into account in determining whether a Closing Date
Material Adverse Effect has occurred or could reasonably be expected to occur to the extent that such event, occurrence, fact,
condition or change has a disproportionate effect on the Borrower and its Subsidiaries taken as a whole, or Celleration and its
Subsidiaries taken as a whole, as the case may be, compared to other participants in the industries in which the Borrower and its
Subsidiaries taken as a whole, or Celleration and its Subsidiaries taken as a whole, as the case may be, conducts its businesses.

 

“Code” means the Internal
Revenue Code of 1986, and the regulations thereunder, in each case as amended, reformed or otherwise modified from time to time.

 

“Collateral” has the
meaning provided in the Pledge and Security Agreement.

 

“Commitment” means the
Lender’s obligation (if any) to make the Loan hereunder.

 

“Commitment Amount” means
$15,500,000.

 

“Commitment Letter” means,
collectively, the Commitment Letter dated as of February 2, 2015 between the Lender and the Borrower regarding the transactions
contemplated hereby, and the outline of the proposed terms and conditions attached thereto.

 

“Compliance Certificate”
means a certificate duly completed and executed by an Authorized Officer of the Borrower, substantially in the form of Exhibit C
hereto, together with such changes thereto as the Lender may from time to time request for the purpose of monitoring the Borrower’s
compliance with the financial covenants contained herein.

 

“Consolidated Total Revenue”
means, for any applicable period, the gross revenue of the Borrower and its Subsidiaries from the sale of Products during such
period, determined on a consolidated basis in accordance with GAAP.

 

“Contingent Liability”
means any agreement, undertaking or arrangement by which any Person guarantees, endorses or otherwise becomes or is contingently
liable upon (by direct or indirect agreement, contingent or otherwise, to provide funds for payment, to supply funds to, or otherwise
to invest in, a debtor, or otherwise to assure a creditor against loss) the Indebtedness of any other Person (other than by endorsements
of instruments in the course of collection), or guarantees the payment of dividends or other distributions upon the Capital Securities
of any other Person. The amount of any Person’s obligation under any Contingent Liability shall (subject to any limitation
set forth therein) be deemed to be the outstanding principal amount of the debt, obligation or other liability guaranteed thereby.

 

    	- 4 -

    	 	 	 

    

 

“Control” is defined
within the definition of “Affiliate”.

 

“Controlled Account”
is defined in Section 7.13(a).

 

“Copyrights” means all
copyrights, whether statutory or common law, and all exclusive and nonexclusive licenses from third parties or rights to use copyrights
owned by such third parties, along with any and all (i) renewals, revisions, extensions, derivative works, enhancements, modifications,
updates and new releases thereof, (ii) income, royalties, damages, claims and payments now and hereafter due and/or payable with
respect thereto, including, without limitation, damages and payments for past, present or future infringements thereof, (iii) rights
to sue for past, present and future infringements thereof, and (iv) foreign copyrights and any other rights corresponding thereto
throughout the world.

 

“Copyright Security Agreement”
means any Copyright Security Agreement executed and delivered by each Loan Party substantially in the form of Exhibit E
to the Pledge and Security Agreement, as amended or otherwise modified from time to time.

 

“Default” means any Event
of Default or any condition, occurrence or event which, after notice or lapse of time or both, would constitute an Event of Default.

 

“Designated Jurisdiction”
means any country or territory to the extent that such country or territory is the subject of any Sanction.

 

“Device” means any instrument,
apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component,
part, or accessory, which is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment,
or prevention of disease, in man or other animals, or (iii) intended to affect the structure or any function of the body of man
or other animals; and which does not achieve its primary intended purposes through chemical action within or on the body of man
or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes.

 

“Device Clearance Application”
means a premarket approval application submitted under Section 515 of the FD&C Act (21 U.S.C. § 360e), a de novo request
submitted under Section 516(f) of the FD&C Act (21 U.S.C. § 360c(f)), or any premarket notification submitted under Section
510(k) of the FD&C Act (21 U.S.C. § 360(k)) seeking clearance from FDA for a Device that is substantially equivalent to
a legally marketed predicate device (“510(k)”), as defined in the FD&C Act, or any corresponding foreign
application in any other jurisdiction.

 

“Disposition” (or similar
words such as “Dispose”) means any sale, transfer, lease, contribution or other conveyance (including by way
of merger) of, or the granting of options, warrants or other rights to, any Loan Party’s assets (including accounts receivable
and Capital Securities of Subsidiaries) to any other Person (other than to the Borrower or one of its wholly owned Subsidiaries)
in a single transaction or series of transactions.

 

    	- 5 -

    	 	 	 

    

 

“Dollars” and the sign
“$” mean lawful money of the United States.

 

“Early Prepayment Fee”
means (i) with respect to any prepayment of the Loan during the period from the Closing Date up to (and including) the first anniversary
of the Closing Date, an amount equal to 5.00% of the principal amount of the Loan being prepaid, (ii) with respect to any prepayment
of the Loan during the period from the day following the first anniversary of the Closing Date up to (and including) the second
anniversary of the Closing Date, an amount equal to 3.00% of the principal amount of the Loan being prepaid, and (iii) with respect
to any prepayment of the Loan during the period from the day following the second anniversary of the Closing Date up to (and including)
the third anniversary of the Closing Date, an amount equal to 2.00% of the principal amount of the Loan being prepaid.

 

“Earn-Out Payments” means,
collectively, the Earn-Out Consideration and the MIST Payments, as such terms are defined in the Merger Agreement.

 

“Environmental Laws”
means all federal, state, local or international laws, statutes, rules, regulations, codes, directives, treaties, requirements,
ordinances, orders, decrees, judgments, injunctions, notices or binding agreements issued, promulgated or entered into by any Governmental
Authority, relating in any way to the environment, natural resources, Hazardous Material or health and safety matters.

 

“Environmental Liability”
means any liability, loss, claim, suit, action, investigation, proceeding, damage, commitment or obligation, contingent or otherwise
(including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), of or affecting any
Loan Party directly or indirectly arising from, in connection with or based upon (i) any Environmental Law or Environmental Permit,
(ii) the generation, use, handling, transportation, storage, treatment, recycling, presence, disposal, Release or threatened Release
of, or exposure to, any Hazardous Materials or (iii) any contract, agreement, penalty, order, decree, settlement, injunction or
other arrangement (including operation of law) pursuant to which liability is assumed, entered into, inherited or imposed with
respect to any of the foregoing.

 

“Environmental Permit”
is defined in Section 6.7(c).

 

“ERISA” means the Employee
Retirement Income Security Act of 1974, as amended, and any successor statute thereto of similar import, together with the regulations
thereunder, in each case as in effect from time to time. References to Sections of ERISA also refer to any successor Sections thereto.

 

“ERISA Affiliate” means
any person that for purposes of Title I and Title IV of ERISA and Section 412 of the Code would be deemed to be a single employer
with the Borrower, pursuant to Section 414(b), (c), (m) or (o) of the Code or Section 4001 of ERISA.

 

    	- 6 -

    	 	 	 

    

 

“ERISA Event” means (a)
any reportable event, as defined in Section 4043 of ERISA, with respect to a Pension Plan, as to which PBGC has not by regulation
waived the requirement of Section 4043(a) of ERISA that it be notified of such event, (b) the filing of a notice of intent to terminate
any Pension Plan, if such termination would require material additional contributions in order to be considered a standard termination
within the meaning of Section 4041(b) of ERISA, the filing under Section 4041(c) of ERISA of a notice of intent to terminate
any Pension Plan or the termination of any Pension Plan under Section 4041(c) of ERISA, (c) the institution of proceedings under
Section 4042 of ERISA by the PBGC for the termination of, or the appointment of a trustee to administer, any Pension Plan, (d)
any failure by any Pension Plan to satisfy the minimum funding requirements of Sections 412 and 430 of the Code or Section 302
of ERISA applicable to such Pension Plan, whether or not waived, (e) the failure to make a required contribution to any Pension
Plan that would result in the imposition of a Lien on any Loan Party or any ERISA Affiliate under Section 303(k) of ERISA or Section
430(k) of the Code, or at any time prior to date hereof, a filing under Section 412 of the Code or Section 302 of ERISA of any
request for a minimum funding variance with respect to any Pension Plan or Multiemployer Plan, (f) an engagement in a non-exempt
prohibited transaction within the meaning of Section 4975 of the Code or Section 406 of ERISA with respect to which a Loan Party
would incur liability which would reasonably be expected to have a Material Adverse Effect, (g) the complete or partial withdrawal
of any Loan Party or any material ERISA Affiliate from a Multiemployer Plan, (h) any Loan Party or an ERISA Affiliate incurring
any material liability under Title IV of ERISA with respect to any Pension Plan (other than premiums due and not delinquent under
Section 4007 of ERISA) and (i) a determination that any Pension Plan is, or is expected to be, in “at risk” status
(as defined in Section 303(i)(4) of ERISA or Section 430(i)(4) of the Code).

 

“Event of Default” is
defined in Section 9.1.

 

“Event
of Loss” means, with respect to any asset of any Loan Party, any of the following:
(i) any loss, destruction or damage of such asset, (ii) any pending or threatened institution of any proceedings for the condemnation
or seizure of such asset or of any right of eminent domain, or (iii) any actual condemnation, seizure or taking, by exercise of
the power of eminent domain or otherwise, of such asset, or confiscation of such asset or requisition of the use of such asset.

 

“Excluded Business” means
any business the Borrower and the Lender may mutually agree upon in writing on or prior to the Closing Date.

 

“Excluded Business Disposition”
means the Disposal of the Excluded Business, in whole or in part, in one or more transactions.

 

“Excluded Taxes” means
any of the following Taxes imposed on or with respect to the Lender or required to be withheld or deducted from a payment to the
Lender: (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each
case: (i) imposed as a result of the Lender being organized under the Laws of, or having its principal office or, in the case of
the Lender, its lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof); or (ii) that
are Other Connection Taxes; (b) U.S. federal withholding Taxes imposed on amounts payable to or for the account of the Lender with
respect to an applicable interest in the Loan pursuant to a Law in effect on the date on which: (i) the Lender acquires such interest
in the Loan; or (ii) the Lender changes its lending office, except in each case to the extent that, pursuant to Section 4.3(a),
amounts with respect to such Taxes were payable either to the Lender's assignor immediately before the Lender became a party hereto
or to the Lender immediately before it changed its lending office; (c) Taxes attributable to the Lender’s failure to comply
with Section 4.3(e); and (d) any Taxes imposed pursuant to FATCA.

 

    	- 7 -

    	 	 	 

    

 

“Exchange Act” means
the Securities Exchange Act of 1934.

 

“Expense Deposit” means
an amount equal to $50,000 deposited by the Borrower with the Lender to be applied to the expenses of the Lender pursuant to Section
11.3.

 

“FATCA” means Sections
1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable
and not materially more onerous to comply with) and any current or future regulations or official interpretations thereof, any
agreements entered into pursuant to Section 1471(b)(1) of the Code and any intergovernmental agreement entered into in connection
with the implementation of such sections of the Code and any U.S. or non-U.S. fiscal or regulatory legislation, rules or official
practices which facilitate the implementation of the foregoing.

 

“FDA” means the U.S.
Food and Drug Administration and any successor entity.

 

“FD&C Act” means
the U.S. Food, Drug and Cosmetic Act of 1938 (or any successor thereto), as amended from time to time, and the rules and regulations
promulgated thereunder.

 

“Fiscal Quarter” means
a quarter ending on the last day of March, June, September or December.

 

“Fiscal Year” means any
period of twelve consecutive calendar months ending on December 31; references to a Fiscal Year with a number corresponding to
any calendar year (e.g., the “2014 Fiscal Year”) refer to the Fiscal Year ending on December 31 of such
calendar year.

 

“Foreign Lender” means
(a) if the Borrower is a U.S. Person, a Lender that is not a U.S. Person, and (b) if the Borrower is not a U.S. Person, a Lender
that is resident or organized under the laws of a jurisdiction other than that in which the Borrower is resident for tax purposes.

 

“F.R.S. Board” means
the Board of Governors of the Federal Reserve System or any successor thereto.

 

“GAAP” is defined in
Section 1.4.

 

“Governmental Authority”
means any national, supranational, federal, state, county, provincial, local, municipal or other government or political subdivision
thereof (including any Regulatory Authority), whether domestic or foreign, and any agency, authority, commission, ministry, instrumentality,
regulatory body, court, tribunal, arbitrator, central bank or other Person exercising executive, legislative, judicial, taxing,
regulatory or administrative powers or functions of or pertaining to any such government.

 

“Guarantors” means, collectively,
each Subsidiary of the Borrower, including Celleration and its Subsidiaries.

 

    	- 8 -

    	 	 	 

    

 

“Hazardous Material”
means any material, substance, chemical, mixture or waste which is capable of damaging or causing harm to any living organism,
the environment or natural resources, including all explosive, special, hazardous, polluting, toxic, industrial, dangerous, biohazardous,
medical, infectious or radioactive substances, materials or wastes, noise, odor, electricity or heat, and including petroleum or
petroleum products, byproducts or distillates, asbestos or asbestos-containing materials, urea formaldehyde, polychlorinated biphenyls,
radon gas, ozone-depleting substances, greenhouse gases, and all other substances or wastes of any nature regulated pursuant to
any Environmental Law or as to which any Governmental Authority requires investigation, reporting or remedial action.

 

“Hedging Agreement” means
any interest rate, foreign currency, commodity, credit or equity swap, collar, cap, floor or forward rate agreement, or other agreement
or arrangement designed to protect against fluctuations in interest rates or currency, commodity or equity values (including any
option with respect to any of the foregoing and any combination of the foregoing agreements or arrangements), and any confirmation
executed in connection with any such agreement or arrangement.

 

“Hedging Obligations”
means, with respect to any Person, all liabilities of such Person under currency exchange agreements, interest rate swap agreements,
interest rate cap agreements and interest rate collar agreements, and all other agreements or arrangements designed to protect
such Person against fluctuations in interest rates or currency exchange rates.

 

“herein”, “hereof”,
“hereto”, “hereunder” and similar terms contained in any Loan Document refer to such Loan
Document as a whole and not to any particular Section, paragraph or provision of such Loan Document.

 

“Impermissible Qualification”
means any qualification or exception to the opinion or certification of any independent public accountant as to any financial statement
of the Loan Parties (i) which is of a “going concern” or similar nature, (ii) which relates to the limited scope of
examination of matters relevant to such financial statement or (iii) which relates to the treatment or classification of any item
in such financial statement and which, as a condition to its removal, would require an adjustment to such item the effect of which
would be to cause the Borrower to be in Default.

 

“including” and “include”
means including without limiting the generality of any description preceding such term, and, for purposes of each Loan Document,
the parties hereto agree that the rule of ejusdem generis shall not be applicable to limit a general statement, which is followed
by or referable to an enumeration of specific matters, to matters similar to the matters specifically mentioned.

 

“IDE” means an application,
including an application filed with any Governmental Authority, for authorization to commence human clinical studies, including
(i) an Investigational Device Exemption as defined in the FD&C Act or any successor application or procedure filed with the
FDA, (ii) an abbreviated IDE as specified in FDA regulations in 21 C.F.R. § 812.2(b), (iii) any equivalent of a United States
IDE in other countries or regulatory jurisdictions, (iv) all amendments, variations, extensions and renewals thereof that may be
filed with respect to the foregoing and (v) all related documents and correspondence thereto, including documents and correspondence
with Institutional Review Boards (IRBs).

 

    	- 9 -

    	 	 	 

    

 

“IND” means (i)
(x) an investigational new drug application (as defined in the FD&C Act) that is required to be filed
with the FDA before beginning clinical testing in human subjects, or any successor application or procedure and (y) any similar
application or functional equivalent relating to any investigational new drug application applicable to or required by any country,
jurisdiction or Governmental Authority other than the U.S. and (ii) all supplements and amendments that may be filed with respect
to the foregoing.

 

“Indebtedness” of any
Person means:

 

(a) all obligations of such Person
for borrowed money or advances and all obligations of such Person evidenced by bonds, debentures, notes or similar instruments;

 

(b) all obligations, contingent
or otherwise, relative to the face amount of all letters of credit, whether or not drawn, and banker’s acceptances issued
for the account of such Person;

 

(c) all Capitalized Lease Liabilities
of such Person;

 

(d) net Hedging Obligations of
such Person and all obligations of such Person arising under Synthetic Leases;

 

(e) all obligations issued, undertaken
or assumed as the deferred purchase price of property or services, including earnouts payable in cash, purchase price adjustments
and seller notes in connection with acquisitions permitted hereunder (to the extent due and payable and included as a liability
on the balance sheet in accordance with GAAP) (other than trade payables entered into in the ordinary course of business);

 

(f) whether or not so included
as liabilities in accordance with GAAP, all obligations of such Person to pay the deferred purchase price of property or services
(excluding trade accounts payable in the ordinary course of business which are not overdue for a period of more than 90 days or,
if overdue for more than 90 days, as to which a dispute exists and adequate reserves in conformity with GAAP have been established
on the books of such Person), and indebtedness secured by (or for which the holder of such indebtedness has an existing right,
contingent or otherwise, to be secured by) a Lien on property owned or being acquired by such Person (including indebtedness arising
under conditional sales or other title retention agreements), whether or not such indebtedness shall have been assumed by such
Person or is limited in recourse;

 

(g) all obligations for any Earn-Out
Payments; and

 

(h) all Contingent Liabilities
of such Person in respect of any of the foregoing.

 

The Indebtedness of any Person shall include the Indebtedness
of any other Person (including any partnership in which such Person is a general partner) to the extent such Person is liable therefor
as a result of such Person’s ownership interest in or other relationship with such Person, except to the extent the terms
of such Indebtedness provide that such Person is not liable therefor.

 

    	- 10 -

    	 	 	 

    

 

“Indemnified Liabilities”
is defined in Section 11.4.

 

“Indemnified Parties”
is defined in Section 11.4.

 

“Indemnified Taxes” means
(i) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of any
Loan Party under any Loan Document and (ii) to the extent not otherwise described in (i), Other Taxes.

 

“Infringement” and “Infringes”
mean the misappropriation of know-how, trade secrets and/or confidential information.

 

“Intellectual Property”
means all (i) Patents, (ii) Trademarks, (iii) Copyrights and other works of authorship (registered or unregistered), and all applications,
registrations and renewals therefor, (iv) Product Authorizations, (v) Product Agreements, (vi) computer software, databases, data
and documentation, (vii) trade secrets and confidential business information, whether patentable or unpatentable and whether or
not reduced to practice, know-how, inventions, manufacturing processes and techniques, research and development information, data
and other information included in or supporting Product Authorizations, (viii) financial, marketing and business data, pricing
and cost information, business, finance and marketing plans, customer and prospective customer lists and information, and supplier
and prospective supplier lists and information, (ix) other intellectual property or similar proprietary rights, (x) copies and
tangible embodiments of any of the foregoing (in whatever form or medium) and (xi) any and all improvements to any of the foregoing.

 

“Interest Period” means,
(i) initially, for the Loan made hereunder, the period beginning on (and including) the date on which the Loan is made hereunder
pursuant to Section 2.2 and ending on (and including) the last day of the calendar month in which the Loan was made, and
(ii) thereafter, the period beginning on (and including) the first day of each succeeding calendar month and ending on the earlier
of (and including) (x) the last day of such calendar month and (y) the Maturity Date.

 

“Investment” means, relative
to any Person, (i) any loan, advance or extension of credit made by such Person to any other Person, including the purchase by
such Person of any bonds, notes, debentures or other debt securities of any other Person, (ii) Contingent Liabilities in favor
of any other Person and (iii) any Capital Securities held by such Person in any other Person. The amount of any Investment shall
be the original principal or capital amount thereof less all returns of principal or equity thereon and shall, if made by the transfer
or exchange of property other than cash, be deemed to have been made in an original principal or capital amount equal to the fair
market value of such property at the time of such Investment.

 

“Key Permits” means all
material Permits relating to the Products (including all Product Authorizations) set forth on Schedule 1.1(a).

 

“Lender” is defined in
the preamble.

 

    	- 11 -

    	 	 	 

    

 

“LIBO Rate” means, with
respect to any applicable Interest Period hereunder, the one-month London Interbank Offered Rate for deposits in Dollars at approximately
11:00 a.m. (London, England time), as determined by the Lender from the appropriate Bloomberg or Telerate page selected by the
Lender (or any successor thereto or similar source reasonably determined by the Lender from time to time), which shall be that
one-month London Interbank Offered Rate for deposits in Dollars in effect two Business Days prior to the first Business Day of
such Interest Period rounded up to the nearest 1/16 of 1%, with such rate to be reset effective as of the first Business Day of
each succeeding Interest Period. If the Loan is advanced other than on the first Business Day of a Fiscal Quarter, the initial
LIBO Rate for the Loan shall be that one-month London Interbank Offered Rate for deposits in Dollars in effect two Business Days
prior to the date of the Loan, which rate shall be in effect until (and including) the last Business Day of the first Interest
Period relative to the Loan. Notwithstanding the foregoing two sentences, in the event that the “LIBO Rate”
is below zero, then the “LIBO Rate” with respect to the Loan will be deemed to be zero. The Lender’s internal
records of applicable interest rates shall be determinative in the absence of manifest error.

 

“Lien” means any security
interest, mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or otherwise), charge
against or interest in property, or other priority or preferential arrangement of any kind or nature whatsoever, to secure payment
of a debt or performance of an obligation.

 

“Loan” is defined in
Section 2.1.

 

“Loan Documents” means,
collectively, this Agreement, the Notes, the Pledge and Security Agreement, the Copyright Security Agreement, the Patent Security
Agreement, the Trademark Security Agreement, the Warrant, the Subordination Agreement, each other agreement pursuant to which the
Lender is granted a Lien to secure the Obligations, the Commitment Letter and each other agreement, certificate, document or instrument
delivered in connection with any Loan Document, whether or not specifically mentioned herein or therein.

 

“Loan Parties” means,
collectively, the Borrower and each Guarantor.

 

“Loan Request” means
a Loan request and certificate duly executed by an Authorized Officer of the Borrower substantially in the form of Exhibit B
hereto.

 

“Material Adverse Effect”
means a material adverse effect on (i) the business, condition (financial or otherwise), operations, performance, properties or
prospects of the Loan Parties taken as a whole, (ii) the rights and remedies of the Lender under any Loan Document or (iii) the
ability of the Loan Parties to perform their respective Obligations under any Loan Document.

 

“Material Agreements”
means (i) each Borrower Material Contract and each Celleration Material Contract, (ii) each contract or agreement to which any
Loan Party is a party involving aggregate payments of more than $500,000, whether such payments are being made by such Loan Party
to a non-Affiliated Person, or by a non-Affiliated Person to such Loan Party; and (iii) all other contracts or agreements, individually
or in the aggregate, material to the business, operations, assets, prospects, conditions (financial or otherwise), performance
or liabilities of the Loan Parties.

 

    	- 12 -

    	 	 	 

    

 

“Maturity Date” means
the fourth anniversary of the Closing Date.

 

“Merger Agreement” means
the Agreement and Plan of Merger dated as of February 2, 2015, by and among the Borrower, ALQA Cedar, Inc., Celleration, and the
Stockholder Representative.

 

“Merger Transaction”
means, collectively, the acquisition of Celleration by the Borrower pursuant to the Merger Agreement and all other transactions
related thereto, including the transactions contemplated pursuant to this Agreement, including the payment of costs, fees and expenses
related thereto.

 

“MMA” has the meaning
ascribed to such term in the definition of “FDA Requirements”.

 

“Moody’s” means
Moody’s Investors Service, Inc.

 

“Multiemployer Plan”
means a “multiemployer plan” (as defined in Section 4001(a)(3) of

ERISA) that is subject to Title IV of ERISA contributed to for
any employees of a Loan Party or any ERISA Affiliate.

 

“NDA” means (i) (x) a new
drug application (as defined in the FD&C Act) and (y) any similar application or functional equivalent relating to
any new drug application applicable to or required by any country, jurisdiction or Governmental Authority other than the U.S. and
(ii) all supplements and amendments that may be filed with respect to the foregoing.

 

“Net Cash Proceeds” means
when used in respect of (i) any Disposition, (ii) any issuance of any debt or equity securities, or (iii) the receipt of any proceeds
in connection with any Event of Loss suffered, in each case by any Loan Party, the gross proceeds in cash or cash equivalents received
by such Person (including such proceeds subsequently received in respect of noncash consideration initially received and amounts
initially placed in escrow that subsequently become available) from such Disposition, issuance or Event of Loss, less all direct
costs and expenses (including attorneys’ fees) incurred or to be incurred, and all federal, state, local and foreign Taxes
assessed or to be assessed (if any), in connection therewith.

 

“Note” means a promissory
note of the Borrower payable to the Lender, in the form of Exhibit A hereto (as such promissory note may be amended, endorsed
or otherwise modified from time to time), evidencing the aggregate Indebtedness of the Borrower to the Lender resulting from the
outstanding amount of the Loan, and also means all other promissory notes accepted from time to time in substitution therefor or
renewal thereof.

 

“Obligations” means all
obligations (monetary or otherwise, whether absolute or contingent, matured or unmatured) of each Loan Party arising under or in
connection with a Loan Document and the principal of and premium, if any, and interest (including interest accruing during the
pendency of any proceeding of the type described in Section 9.1.8, whether or not allowed in such proceeding) on the Loan.

 

“OFAC” means the Office
of Foreign Assets Control of the United States Department of the Treasury.

 

    	- 13 -

    	 	 	 

    

 

“Organic Document” means,
relative to each Loan Party, its certificate of incorporation, by-laws, certificate of partnership, partnership agreement, certificate
of formation, limited liability agreement, operating agreement and all shareholder agreements, voting trusts and similar arrangements
applicable to such Loan Party’s Capital Securities.

 

“Other Connection Taxes”
means, with respect to the Lender, Taxes imposed as a result of a present or former connection between the Lender and the jurisdiction
imposing such Tax (other than connections arising from the Lender having executed, delivered, become a party to, performed its
obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant
to or enforced any Loan Document, or sold or assigned an interest in the Loan or Loan Document).

 

“Other Taxes” means any
and all stamp, documentary or similar Taxes, or any other excise or property Taxes or similar levies that arise on account of any
payment made or required to be made under any Loan Document or from the execution, delivery, registration, recording or enforcement
of any Loan Document.

 

“Other Administrative Proceeding”
means any administrative proceeding relating to a dispute involving a patent office or other relevant intellectual property registry
which relates to validity, opposition, revocation, ownership or enforceability or the relevant Intellectual Property (other than
Other Connection Taxes imposed with respect to an assignment).

 

“Patent” means any patent,
patent application and invention disclosure, including any divisions, continuations, continuations in-part, provisionals, continued
prosecution applications, substitutions, reissues, reexaminations, renewals, extensions, restorations, supplemental protection
certificates and other additions in connection therewith, whether in or related to the United States or any foreign country or
other jurisdiction.

 

“Patent Security Agreement”
means any Patent Security Agreement executed and delivered by each Loan Party in substantially the form of Exhibit F
to the Pledge and Security Agreement, as amended or otherwise modified from time to time.

 

“PBGC” means the Pension
Benefit Guaranty Corporation, or any entity succeeding to all or any of its functions under ERISA.

 

“PDMA” means the Prescription
Drug Marketing Act.

 

“Pension Plan” means
a “pension plan”, as such term is defined in Section 3(2) of ERISA, which is subject to Title IV of ERISA (other than
a Multiemployer Plan), to which a Loan Party or any ERISA Affiliate sponsors, contributes to, or provides benefits under, or has
any obligation to contribute or provide benefits under, and to which such Loan Party or ERISA Affiliate may have liability, including
any liability by reason of having been a substantial employer under Section 4063 of ERISA at any time during the preceding five
years, or by reason of being deemed to be a contributing sponsor under Section 4069 of ERISA.

 

“Permits” means all permits,
licenses, registrations, certificates, orders, approvals, authorizations, consents, waivers, franchises, variances and similar
rights issued by or obtained from any Governmental Authority or any other Person, including, without limitation, those relating
to Environmental Laws.

 

    	- 14 -

    	 	 	 

    

 

“Permitted Debt” is defined
in Section 8.2.

 

“Permitted Lien” is defined
in Section 8.3.

 

“Person” means any natural
person, corporation, limited liability company, partnership, joint venture, association, trust or unincorporated organization,
Governmental Authority or any other legal entity, whether acting in an individual, fiduciary or other capacity.

 

“Pledge and Security Agreement”
means the Pledge and Security Agreement executed and delivered by each Loan Party, substantially in the form of Exhibit D
hereto, as amended or otherwise modified from time to time.

 

“Product” means any current
or future product developed, manufactured, licensed, marketed, sold or otherwise commercialized by any Loan Party, including any
such product in development or which may be developed.

 

“Product Agreement” means
each agreement, license, document, instrument, interest (equity or otherwise) or the like under which one or more Persons grants
or receives any right, title or interest with respect to any Product Development and Commercialization Activities in respect of
one or more Products specified therein, or receives or is granted the right to exclude any third parties from engaging in any Product
Development and Commercialization Activities with respect thereto, including each contract or agreement with suppliers, manufacturers,
distributors, clinical research organizations, wholesalers, pharmacies or with any other Person related to any such entity.

 

“Product Authorizations”
means any and all approvals (including applicable supplements, amendments, pre and post approvals, drug master files, governmental
price and reimbursement approvals and approvals of applications for regulatory exclusivity), licenses, registrations or authorizations
of any Governmental Authority necessary for the manufacture, development, distribution, use, storage, import, export, transport,
promotion, marketing, sale or other commercialization of a Product in any country or jurisdiction, including without limitation
INDs, NDAs, BLAs, IDEs, Device Clearance Applications or similar applications.

 

“Product Development and Commercialization
Activities” means, with respect to any Product, any combination of research, development, manufacture, importation, use,
sale, storage, design, labeling, marketing, promotion, supply, distribution, testing, packaging, purchasing or other commercialization
activities, receipt of payment in respect of any of the foregoing, or like activities the purpose of which is to commercially exploit
such Product.

 

“Prohibited Payment”
means any bribe, rebate, payoff, influence payment, kickback or other payment or gift of money or anything of value (including
meals or entertainment) to any officer, employee or ceremonial office holder of any government or instrumentality thereof, political
party or supra-national organization (such as the United Nations), any political candidate, any royal family member or any other
person who is connected or associated personally with any of the foregoing that is prohibited under any applicable law or regulation
or otherwise for the purpose of influencing any act or decision of such payee in his official capacity, inducing such payee to
do or omit to do any act in violation of his lawful duty, securing any improper advantage or inducing such payee to use his influence
with a government or instrumentality thereof to affect or influence any act or decision of such government or instrumentality.

 

    	- 15 -

    	 	 	 

    

 

“Regulatory Authority”
means any Governmental Authority that is concerned with or has regulatory oversight with respect to the use, control, safety, efficacy,
reliability, manufacturing, marketing, distribution, sale or other Product Development and Commercialization Activities relating
to any Product of a Loan Party, including the FDA and all equivalent of such agencies in other jurisdictions, and includes Standard
Bodies.

 

“Regulatory
Authorizations” means, with respect to the Products, all approvals, clearances, authorizations, orders, exemptions, registrations,
certifications, licenses and Permits granted by any Regulatory Authorities, including all NDAs, BLAs, IDEs, Device Clearance Applications
and Product Authorizations held by the Loan Parties or any of their respective licensors, as applicable, or that are pending before
the FDA or equivalent non-United States Governmental Entity with respect to the Products.

 

“Release” means any releasing,
disposing, discharging, injecting, spilling, leaking, leaching, pumping, pouring, dumping, depositing, emitting, escaping, emptying,
seeping, dispersal, migrating or placing, including movement through, into or upon the environment or any natural or man-made structure.

 

“Restricted Payment”
means (i) the declaration or payment of any dividend (other than dividends payable solely in Capital Securities of a Loan Party)
on, or the making of any payment or distribution on account of, or setting apart assets for a sinking or other analogous fund for
the purchase, redemption, defeasance, retirement or other acquisition of, any class of Capital Securities of a Loan Party or any
warrants, options or other right or obligation to purchase or acquire any such Capital Securities, whether now or hereafter outstanding
or (ii) the making of any other distribution in respect of such Capital Securities, in each case either directly or indirectly,
whether in cash, property or obligations of a Loan Party or otherwise.

 

“S&P” means Standard
& Poor’s Financial Services LLC, a part of McGraw Hill Financial.

 

“Sanction” means any
international economic sanction administered or enforced by the

United States Government (including, without limitation, OFAC),
the United Nations Security

Council, the European Union or its Member States, Her Majesty’s
Treasury or other relevant sanctions authority.

 

“SEC” means the Securities
and Exchange Commission.

 

    	- 16 -

    	 	 	 

    

 

“Solvent” means, with
respect to the Borrower and its Subsidiaries on a particular date, that on such date (i) the fair value of the property of the
Borrower and its Subsidiaries on a consolidated basis is greater than the total amount of liabilities, including Contingent Liabilities,
of the Borrower and its Subsidiaries on a consolidated basis, (ii) the present fair saleable value of the assets of the Borrower
and its Subsidiaries on a consolidated basis is not less than the amount that will be required to pay the probable liability of
the Borrower and its Subsidiaries on a consolidated basis on its debts as they become absolute and matured, (iii) the Borrower
does not intend to, and does not believe that it or its Subsidiaries will, incur debts or liabilities beyond the ability of the
Borrower and its Subsidiaries to pay as such debts and liabilities mature, (iv) the Borrower and its Subsidiaries on a consolidated
basis are not engaged in business or a transaction, and the Borrower and its Subsidiaries on a consolidated basis are not about
to engage in a business or a transaction, for which the property of the Borrower and its Subsidiaries on a consolidated basis would
constitute an unreasonably small capital and (v) the Borrower and its Subsidiaries have not executed this Agreement or any other
Loan Document or made any transfer or incurred any obligations hereunder, with actual intent to hinder, delay or defraud either
present or future creditors. The amount of Contingent Liabilities at any time shall be computed as the amount that, in light of
all the facts and circumstances existing at such time, can reasonably be expected to become an actual or matured liability.

 

“Sources and Uses Certificate”
means a certificate, required to be delivered pursuant to Section 5.1.6, duly executed and completed by an Authorized Officer
of the Borrower setting forth the sources and uses of the cash and equity proceeds to be used to consummate the Merger Transaction.

 

“Standard Bodies” means
any of the organizations that create, sponsor and maintain safety, quality or other standards, including ISO, ANSI, CEN and SCC
and the like.

 

“Subordination Agreement”
means the Intercompany Subordination Agreement executed and delivered by each Loan Party, substantially in the form of Exhibit
K hereto, as amended or otherwise modified from time to time.

 

“Subsidiary” means, with
respect to any Person, any other Person of which more than 50% of the outstanding Voting Securities of such other Person (irrespective
of whether at the time Capital Securities of any other class or classes of such other Person shall or might have voting power upon
the occurrence of any contingency) is at the time directly or indirectly owned or controlled by such Person, by such Person and
one or more other Subsidiaries of such Person, or by one or more other Subsidiaries of such Person. Unless the context otherwise
specifically requires, the term “Subsidiary” shall be a reference to a Subsidiary of the Borrower.

 

“Synthetic Lease” means,
as applied to any Person, any lease (including leases that may be terminated by the lessee at any time) of any property (whether
real, personal or mixed) (i) that is not a capital lease in accordance with GAAP and (ii) in respect of which the lessee retains
or obtains ownership of the property so leased for federal income tax purposes, other than any such lease under which that Person
is the lessor.

 

“Taxes” means all income,
stamp or other taxes, duties, levies, imposts, charges, assessments, fees, deductions or withholdings, now or hereafter imposed,
levied, collected, withheld or assessed by any Governmental Authority, and all interest, penalties or similar liabilities with
respect thereto.

 

“Termination Date” means
the date on which all Obligations have been paid in full in cash and the Commitment shall have terminated.

 

    	- 17 -

    	 	 	 

    

 

“Trademark” means any
trademark, service mark, trade name, logo, symbol, trade dress, domain name, corporate name and other indicator of source or origin,
and all applications and registrations therefor, together with all of the goodwill associated with the therewith.

 

“Trademark Security Agreement”
means any Trademark Security Agreement executed and delivered by each Loan Party substantially in the form of Exhibit G
to the Pledge and Security Agreement, as amended or otherwise modified from time to time.

 

“U.S. Person” means any
Person that is a “United States Person” as defined in Section 7701(a)(30) of the Code.

 

“U.S. Tax Compliance Certificate”
is defined in Section 4.3(e)(ii)(b)(3).

 

“UCC” means the Uniform
Commercial Code as in effect from time to time in the State of New York; provided that, if, with respect to any financing
statement or by reason of any provisions of law, the perfection or the effect of perfection or non-perfection of the security interests
granted to the Lender pursuant to the applicable Loan Document is governed by the Uniform Commercial Code as in effect in a jurisdiction
of the United States other than New York, then “UCC” means the Uniform Commercial Code as in effect from time to time
in such other jurisdiction for purposes of the provisions of each Loan Document and any financing statement relating to such perfection
or effect of perfection or non-perfection.

 

“United States” or “U.S.”
means the United States of America, its fifty states and the District of Columbia.

 

“Voting Securities” means,
with respect to any Person, Capital Securities of any class or kind ordinarily having the power to vote for the election of directors,
managers or other voting members of the governing body of such Person.

 

“Warrant” means the warrant
executed and delivered by the Borrower and the Lender, substantially in the form of Exhibit H hereto, as amended or otherwise
modified from time to time.

 

“Welfare Plan” means
a “welfare plan”, as such term is defined in Section 3(1) of ERISA that provides welfare benefits to terminated employees,
other than to the extent required by Section 4980B(f) of the Code and the corresponding provisions of ERISA or similar state law.

 

“wholly owned Subsidiary”
means any direct or indirect Subsidiaries of the Borrower, all of the outstanding Capital Securities of which (other than any director’s
qualifying shares or investments by foreign nationals mandated by applicable laws) is owned directly or indirectly by the Borrower.

 

Section
1.2 Use of Defined Terms. Unless otherwise defined or the context otherwise requires, terms for which meanings are
provided in this Agreement shall have such meanings when used in each other Loan Document and the schedules attached hereto.

 

Section
1.3 Cross-References. Unless otherwise specified, references in a Loan Document to any Article or Section are references
to such Article or Section of such Loan Document, and references in any Article, Section or definition to any clause are references
to such clause of such Article, Section or definition.

 

    	- 18 -

    	 	 	 

    

 

Section
1.4 Accounting and Financial Determinations. Unless otherwise specified, all accounting terms used in each Loan Document
shall be interpreted, and all accounting determinations and computations thereunder (including under Section 8.4 and any
definitions used in such calculations) shall be made, in accordance with those generally accepted accounting principles (“GAAP”)
applied in the preparation of the financial statements referred to in Sections 5.1.4(a) and (b) and Sections 7.1(a),
(b), and (c). Unless otherwise expressly provided, all financial covenants and defined financial terms shall be computed
on a consolidated basis for the Borrower and its Subsidiaries, in each case without duplication.

 

Article
II

COMMITMENT and BORROWING procedures

 

Section
2.1 Commitment. On the terms and subject to the conditions of this Agreement, the Lender agrees to make a term loan
(the “Loan”) in a single borrowing to the Borrower on the Closing Date in an amount equal to the Commitment
Amount or such lesser amount requested by the Borrower in the Loan Request, as the case may be. No further borrowings will be made
hereunder, and no amounts paid or prepaid with respect to the Loan may be reborrowed.

 

Section
2.2 Borrowing Procedures. Subject to the terms and conditions hereof, the Borrower may, by delivery of a Loan Request
to the Lender, irrevocably request that the Loan be made by delivering to the Lender a Loan Request on or before 10:00 a.m. on
a Business Day at least three (3) (but not greater than five (5)) Business Days prior to the Closing Date.

 

Section
2.3 Funding. After receipt of the Loan Request for the Loan, the Lender shall, on the Closing Date and subject to
the terms and conditions hereof, make the requested proceeds of the Loan available to the Borrower by wire transfer to the account
the Borrower shall have specified in its Loan Request. All such proceeds shall be applied in accordance with the Sources and Uses
Certificate.

 

Section
2.4 Reduction of the Commitment Amounts. The Commitment Amount shall automatically and permanently be reduced to
zero immediately after the making of the Loan on the Closing Date.

 

Article
III

REPAYMENTS, PREPAYMENTS, INTEREST AND FEES

 

Section
3.1 Repayments and Prepayments; Application. The Borrower agrees that the Loan, and any fees or interest accrued
or accruing thereon, shall be repaid and prepaid solely in Dollars pursuant to the terms of this Article III.

 

Section
3.2 Repayments and Prepayments. The Borrower shall repay in full the entire unpaid principal amount of the Loan on
the Maturity Date. Prior thereto, payments and prepayments of the Loan shall be made as set forth below.

 

    	- 19 -

    	 	 	 

    

 

(a) On the last Business Day of
each calendar month that follows the second anniversary of the Closing Date, the Borrower shall make a scheduled principal payment
on the Loan of $225,000, with any remaining unpaid balance of the Loan being payable in cash on the Maturity Date.

 

(b) The Borrower may, upon five
(5) Business Days prior written notice to the Lender, prepay the outstanding amount of the Loan in whole or in part.

 

(c) Subject to Section 3.4,
upon any Disposition by any Loan Party (other than any Excluded Business Disposition) that, when taken together with all other
such Dispositions made by all Loan Parties during the preceding period of 12 consecutive months, results in aggregate Net Cash
Proceeds from such Dispositions that exceed $500,000 in the aggregate for such 12-month period, the Borrower shall within three
(3) Business Days of such Person’s receipt of such excess proceeds prepay the outstanding principal amount of the Loan in
an amount equal to 100% of such excess Net Cash Proceeds. The provisions of this clause shall not be deemed to be implied consent
to any Disposition otherwise prohibited by the terms and conditions of this Agreement.

 

(d) Subject to Section 3.4,
upon the receipt by any Loan Party of any Event of Loss, that, when taken together with all other proceeds received upon any Events
of Loss by all Loan Parties during the preceding period of 12 consecutive months, exceed $250,000 in the aggregate for such 12-month
period, the Borrower shall within three (3) Business Days of such Person’s receipt of such excess proceeds thereof prepay
the outstanding principal amount of the Loan in an amount equal to 100% of such excess Net Cash Proceeds.

 

(e) Upon any Excluded Business
Disposition by any Loan Party that, when taken together with all other Excluded Business Dispositions, results in Net Cash Proceeds
that exceed $5,000,000 in the aggregate, the Borrower shall within three (3) Business Days of such Person’s receipt of such
excess proceeds prepay the outstanding principal amount of the Loan in an amount equal to 100% of such excess Net Cash Proceeds.

 

(f) Upon the issuance, sale or
other incurrence of any debt securities or other Indebtedness by any Loan Party (other than Permitted Debt), the Borrower shall,
within three (3) Business Days of such Person’s receipt of the proceeds thereof, prepay the outstanding principal amount
of the Loan in an amount equal to 100% of the Net Cash Proceeds therefrom. The provisions of this clause shall not be deemed to
be implied consent to any such issuance, sale or incurrence otherwise prohibited by the terms and conditions of this Agreement.

 

(g) Immediately upon any acceleration
of the Maturity Date of the Loan pursuant to Section 9.2 or Section 9.3, the Borrower shall repay the Loan in full,
unless, pursuant to Section 9.3, only a portion of the Loan are so accelerated (in which case the portion so accelerated
shall be so repaid).

 

    	- 20 -

    	 	 	 

    

 

(h) Any term or provision hereof
to the contrary notwithstanding, if the Loan hereunder is repaid or prepaid for any reason on or prior to the date that is three
(3) years after the Closing Date (including repayments and prepayments made pursuant to clause (b) through (g) above, but excluding,
payments made pursuant to clause (a) of this Section 3.2), the Borrower shall pay the Early Prepayment Fee to the
Lender at the time of such prepayment, together with all other fees payable hereunder (if any), including pursuant to Sections
3.7 and 3.8.

 

Section
3.3 Application. Amounts repaid or prepaid in respect of the Loan shall be applied as set forth in this Section
3.3.

 

(a) Subject to clause (b),
proceeds of each prepayment or repayment of the Loan shall be applied as set forth in clause (b) of Section 4.4.

 

(b) Each prepayment of the Loan
made pursuant to clauses (b), (c), (d), (e) or (f) of Section 3.2 shall be applied
in reverse order of the scheduled repayments set forth in clause (a) of Section 3.2.

 

Section
3.4 Reinvestment of Certain Proceeds. Notwithstanding clauses (c) and (d) of Section 3.2, up
to an aggregate amount of $2,500,000 of Net Cash Proceeds that would otherwise be required to be used to prepay the Loan may instead
be used to replace, repair or restore the properties or assets used (i) in any Loan Party’s business or to acquire other
properties or assets related to any Loan Party’s business or (ii) otherwise for working capital purposes in connection with
the Borrower’s would care business; provided that, (a) no Default or Event of Default has occurred and is continuing
on the date such Person receives such proceeds, and (b) the Borrower delivers a certificate to the Lender within five (5) Business
Days after the date of such receipt stating that such proceeds shall be so used within one hundred eighty (180) days after the
receipt of such proceeds. If all or any portion of such proceeds not so applied to the prepayment of the Loan are not used in accordance
with the preceding sentence within such period or an Event of Default shall have occurred and is continuing, such remaining portion
shall be applied to prepay the Loan as required by Section 3.2 on the last day of such specified period, or immediately
in the case of an Event of Default.

 

Section
3.5 Interest Rate. During any applicable Interest Period, the Loan shall accrue interest during such Interest Period
at a rate per annum equal to the sum of (i) the greater of (x) the LIBO Rate for such Interest Period and (y) 1.00%, plus
(ii) the Applicable Margin. The interest rate shall be recalculated and, if necessary, adjusted for each Interest Period, in each
case pursuant to the terms hereof.

 

Section
3.6 Default Rate. At all times commencing upon the date any Event of Default occurs, and continuing until such Event
of Default is no longer continuing, the Applicable Margin shall be increased by 4.00% per annum.

 

Section
3.7 Payment Dates. Interest accrued on the Loan shall be payable in cash, without duplication:

 

(a) on the Maturity Date therefor;

 

(b) on the date of any payment
or prepayment, in whole or in part, of principal outstanding on the Loan, on the principal amount so paid or prepaid;

 

    	- 21 -

    	 	 	 

    

 

(c) the last day of each Interest
Period for the Loan; provided that if such day is not a Business Day, then such payment shall be made on the next succeeding
Business Day; and

 

(d) on that portion of the Loan
that is accelerated pursuant to Section 9.2 or Section 9.3, immediately upon such acceleration.

 

Interest accrued on the Loan or any other monetary Obligations
after the date such amount is due and payable (whether on the Maturity Date, upon acceleration or otherwise) shall be payable upon
demand.

 

Section
3.8 Exit Fee. On the day when the Loan is paid in full, whether by voluntary or involuntary prepayment, scheduled
amortization, acceleration, on the Maturity Date or otherwise, the Borrower will pay an exit fee equal to the greater of (i) one
percent (1%) multiplied by the remaining outstanding principal balance of the Loan immediately prior to the final payment of the
Loan and (ii) $100,000.

 

Section
3.9 Fees. The Borrower shall pay to the Lender such fees as shall have been separately agreed in the Commitment Letter.

 

Article
IV

LIBO RATE AND OTHER PROVISIONS

 

Section
4.1 Increased Costs, Etc. If any Change in Law shall (i) impose, modify or deem applicable any reserve, special deposit,
compulsory loan, insurance charge or similar requirement against assets of, deposits with or for the account of, or credit extended
by, the Lender or any Person controlling the Lender (except any reserve requirement reflected in the LIBO Rate) or (ii) impose
on the Lender or the London interbank market any other condition, cost or expense (other than Taxes) affecting this Agreement or
the Loan made by the Lender, and the result of any of the foregoing shall be to increase the cost to the Lender of making, converting
to, continuing or maintaining the Loan or of maintaining its obligation to make the Loan (whether of principal, interest
or any other amount) then, upon written notice from the Lender, the Borrower shall within 30 days following receipt of such notice
pay directly to the Lender such additional amount or amounts sufficient to compensate the Lender for such additional costs incurred
or reduction suffered. A certificate of the Lender setting forth the amount or amounts necessary to compensate the Lender or a
Person controlling the Lender, as the case may be, as specified in this Section 4.1 and delivered to the Borrower, shall
be conclusive absent manifest error. Failure or delay on the part of the Lender to demand compensation pursuant to this Section
4.1 shall not constitute a waiver of the Lender’s right to demand such compensation; provided that the Borrower
shall not be required to compensate the Lender pursuant to this Section 4.1 for any increased costs incurred or reductions
suffered more than nine months prior to the date that the Lender notifies the Borrower of the Change in Law giving rise to such
increased costs or reductions, and of the Lender’s intention to claim compensation therefor (except that, if the Change in
Law giving rise to such increased costs or reductions is retroactive, then the nine-month period referred to above shall be extended
to include the period of retroactive effect thereof).

 

    	- 22 -

    	 	 	 

    

 

Section
4.2 Increased Capital Costs. If any Change in Law affects or would affect the amount of capital required or expected
to be maintained by the Lender or any Person controlling the Lender, and the Lender determines (in good faith but in its sole and
absolute discretion) that the rate of return on its or such controlling Person’s capital as a consequence of the Commitment
or the Loan made by it hereunder is reduced to a level below that which the Lender or such controlling Person could have achieved
but for the occurrence of any such circumstance, then upon notice from time to time by the Lender to the Borrower, the Borrower
shall within five days following receipt of such notice pay directly to the Lender additional amounts sufficient to compensate
the Lender or such controlling Person for such reduction in rate of return. A statement of the Lender as to any such additional
amount or amounts shall, in the absence of manifest error, be conclusive and binding on the Borrower. In determining such amount,
the Lender may use any method of averaging and attribution that it (in its sole and absolute discretion) shall deem applicable.

 

Section
4.3 Taxes. The Borrower covenants and agrees as follows with respect to Taxes.

 

(a) Payments Free of Taxes.
Any and all payments by the Borrower under any Loan Document shall be made without setoff, counterclaim or other defense, and free
and clear of, and without deduction or withholding for or on account of, any Taxes, except as required by Law. If any applicable
law (as determined in the good faith discretion of the Borrower) requires the deduction or withholding of any Tax from any such
payment, then the Borrower shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted
or withheld to the relevant Governmental Authority in accordance with applicable law and, if such Tax is an Indemnified Tax, then
the sum payable by the Borrower shall be increased as necessary so that after such deduction or withholding has been made (including
such deductions and withholdings applicable to additional sums payable under this Section) the applicable recipient receives an
amount equal to the sum it would have received had no such deduction or withholding been made.

 

(b) Payment of Other Taxes
by Borrower. The Borrower shall timely pay all Other Taxes to the relevant Governmental Authority imposing such Other Taxes
in accordance with applicable law.

 

(c) Evidence of Payments.
As promptly as practicable after the payment of any Taxes or Other Taxes, and in any event within 45 days of any such payment being
due, the Borrower shall furnish to the Lender a copy of an official receipt (or a certified copy thereof) evidencing the payment
of such Taxes or Other Taxes.

 

(d) Indemnification. The
Borrower shall indemnify the Lender for any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable
to amounts payable under this Section) levied, imposed or assessed on (and whether or not paid directly by) the Lender, within
10 days after demand therefor, whether or not such Indemnified Taxes are correctly or legally asserted by the relevant Governmental
Authority. A certificate as to the amount of such payment or liability delivered to the Borrower by the Lender shall be conclusive
absent manifest error.

 

    	- 23 -

    	 	 	 

    

 

(e) Status of Lender.

 

(i) If
the Lender is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document
shall deliver to the Borrower, at the time or times reasonably requested by the Borrower, such properly completed and executed
documentation reasonably requested by the Borrower as will permit such payments to be made without withholding or at a reduced
rate of withholding. In addition, the Lender, if reasonably requested by the Borrower, shall deliver such other documentation prescribed
by applicable law or reasonably requested by the Borrower as will enable the Borrower to determine whether or not the Lender is
subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding
two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in Sections
4.3(e)(ii)(A), (ii)(B), (ii)(C) and 4.3(f) below) shall not be required if in the Lender’s reasonable
judgment such completion, execution or submission would subject the Lender to any material unreimbursed cost or expense or would
materially prejudice the legal or commercial position of the Lender.

 

(ii) Without
limiting the generality of the foregoing:

 

(A)         if
the Lender is a U.S. Person, it shall deliver to the Borrower on or prior to the date on which the Lender becomes a Lender under
this Agreement (and from time to time thereafter upon the reasonable request of the Borrower), executed copies of IRS Form W-9
certifying that the Lender is exempt from U.S. federal backup withholding tax;

 

(B)         if
the Lender is a Foreign Lender, it shall, to the extent it is legally entitled to do so, deliver to the Borrower (in such number
of copies as shall be requested by the Borrower) on or prior to the date on which the Foreign Lender becomes a Lender under this
Agreement (and from time to time thereafter upon the reasonable request of the Borrower), whichever of the following is applicable:

 

(1)         in
the case of the Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect
to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN or W-8BEN-E, as applicable, establishing an
exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “interest” article of such tax treaty
and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or 8-BEN-E, as applicable, establishing
an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “business profits” or “other
income” article of such tax treaty;

 

    	- 24 -

    	 	 	 

    

 

(2)         executed
copies of IRS Form W-8ECI;

 

(3)         in
the case of the Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code,
(x) a certificate substantially in the form of Exhibit I-1 to the effect that the Foreign Lender is not a “bank”
within the meaning of Section 881(c)(3)(A) of the Code, a “10 percent shareholder” of the Borrower within the meaning
of Section 881(c)(3)(B) of the Code, or a “controlled foreign corporation” described in Section 881(c)(3)(C) of the
Code (a “U.S. Tax Compliance Certificate”) and (y) executed copies of IRS Form W-8BEN or W-8BEN-E, as applicable;
or

 

(4)         to
the extent the Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY, accompanied by IRS Form W-8ECI,
IRS Form W-8BEN or W-8BEN-E, as applicable, a U.S. Tax Compliance Certificate substantially in the form of Exhibit I-2 or
Exhibit I-3, IRS Form W-9, and/or other certification documents from each beneficial owner, as applicable; provided that
if the Foreign Lender is a partnership and one or more direct or indirect partners of the Foreign Lender are claiming the portfolio
interest exemption, the Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit I-4
on behalf of each such direct and indirect partner;

 

(C)         if
the Lender is a Foreign Lender, it shall, to the extent it is legally entitled to do so, deliver to the Borrower (in such number
of copies as shall be requested by the Borrower) on or prior to the date on which the Foreign Lender becomes a Lender under this
Agreement (and from time to time thereafter upon the reasonable request of the Borrower), executed copies of any other form prescribed
by applicable law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together
with such supplementary documentation as may be prescribed by applicable law to permit the Borrower to determine the withholding
or deduction required to be made; and

 

(f) FATCA. If a payment
made to the Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if the Lender were
to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b)
of the Code, as applicable), the Lender shall deliver to the Borrower at the time or times prescribed by law and at such time or
times reasonably requested by the Borrower such documentation prescribed by applicable Law (including as prescribed by Section
1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower as may be necessary for the
Borrower to comply with their obligations under FATCA and to determine that the Lender has complied with the Lender’s obligations
under FATCA or to determine the amount to deduct and withhold from such payment. Solely for purposes of this Section 4.3(f),
“FATCA” shall include any amendments made to FATCA after the date of this Agreement.

 

    	- 25 -

    	 	 	 

    

 

(g) Maintenance of Forms.
The Lender agrees that if any form or certification it previously delivered pursuant to this Section 4.3 expires or becomes
obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower in writing of
its legal inability to do so.

 

(h) Treatment of Certain Refunds.
If the Lender determines, in its sole discretion, exercised in good faith, that it has received a refund of any Taxes as to which
it has been indemnified by the Borrower or with respect to which the Borrower has paid additional amounts pursuant to this Section,
it shall pay to the Borrower an amount equal to such refund (but only to the extent of indemnity payments made, or additional amounts
paid, by the Borrower under this Section with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses
(including Taxes) incurred by the Lender, and without interest (other than any interest paid by the relevant Governmental Authority
with respect to such refund), provided that the Borrower, upon the request of the Lender, agrees to repay the amount paid over
to any the Borrower (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) to the Lender
in the event the Lender is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary
in this subsection, in no event will the Lender be required to pay any amount to the Borrower pursuant to this subsection the payment
of which would place the Lender in a less favorable net after-Tax position than the Lender would have been in if the indemnification
payments or additional amounts giving rise to such refund had never been paid. This Section 4.3(h) shall not be construed
to require the Lender to make available its tax returns (or any other information relating to its taxes that it deems confidential)
to the Borrower or any other Person.

 

Section
4.4 Payments, Computations; Proceeds of Collateral, Etc. The parties hereto agree as follows:

 

(a) Unless otherwise expressly
provided in a Loan Document, all payments by the Borrower pursuant to each Loan Document shall be made without setoff, deduction
or counterclaim not later than 11:00 a.m. on the date due in same day or immediately available funds to such account as the
Lender shall specify from time to time by notice to the Borrower. Funds received after that time shall be deemed to have been received
by the Lender on the next succeeding Business Day. All interest and fees shall be computed on the basis of the actual number of
days (including the first day but excluding the last day) occurring during the period for which such interest or fee is payable
over a year comprised of three hundred sixty (360) days. Payments due on other than a Business Day shall be made on the next
succeeding Business Day and such extension of time shall be included in computing interest and fees in connection with that payment.

 

    	- 26 -

    	 	 	 

    

 

(b) All amounts received as a
result of the exercise of remedies under the Loan Documents (including from the proceeds of collateral securing the Obligations)
or under applicable law shall be applied upon receipt to the Obligations as follows: (i) first, to the payment in full in cash
of all interest (including interest accruing after the commencement of a proceeding in bankruptcy, insolvency or similar law, whether
or not permitted as a claim under such law) and fees owing under the Loan Documents, and all costs and expenses owing to the Lender
pursuant to the terms of the Loan Documents, until paid in full in cash, (ii) second, after payment in full in cash of the amounts
specified in clause (b)(i), to the payment of the principal amount of the Loan then outstanding, (iii) third, after
payment in full in cash of the amounts specified in clauses (b)(i) and (b)(ii), to the payment of all other Obligations
owing to the Lender, and (iv) fourth, after payment in full in cash of the amounts specified in clauses (b)(i) through
(b)(iii), and following the Termination Date, to the Borrower or any other Person lawfully entitled to receive such surplus.

 

Section
4.5 Setoff. The Lender shall, upon the occurrence and during the continuance of any Event of Default described in
clauses (a) through (d) of Section 9.1.8 or, upon the occurrence and during the continuance of any other Event
of Default, have the right to appropriate and apply to the payment of the Obligations owing to it (whether or not then due), and
(as security for such Obligations) each Loan Party hereby grants to the Lender a continuing security interest in, any and all balances,
credits, deposits, accounts or moneys of each Loan Party then or thereafter maintained with the Lender. The Lender agrees promptly
to notify the Borrower after any such appropriation and application made by the Lender; provided that, the failure to give
such notice shall not affect the validity of such setoff and application. The rights of the Lender under this Section are in addition
to other rights and remedies (including other rights of setoff under applicable law or otherwise) which the Lender may have.

 

Section
4.6 LIBO Rate Not Determinable. If prior to the commencement of any Interest Period, adequate and reasonable means
do not exist for ascertaining the LIBO Rate for such Interest Period, then the Lender shall give notice thereof to the Borrower
as promptly as practicable. In the event of any such determination, the Loan shall, until the Lender has advised the Borrower that
the circumstances giving rise to such notice no longer exist, bear interest at the interest rate in effect for the immediately
preceding Interest Period.

 

Article
V

CONDITIONS TO LOAN

 

Section
5.1 Loan. The obligation of the Lender to make the Loan shall be subject to the execution and delivery of this Agreement
by the parties hereto, the delivery of a Loan Request as requested pursuant to Section 2.2, and the prior or substantially
concurrent satisfaction of each of the conditions precedent set forth below in this Article.

 

Section
5.1.1 Secretary’s Certificate, Etc. The Lender shall have received from each Loan Party, (i) a copy of
a good standing certificate, dated a date reasonably close to the Closing Date, for each such Person and (ii) a certificate,
dated as of the Closing Date, duly executed and delivered by such Person’s Secretary or Assistant Secretary, managing member
or general partner, as applicable, as to:

 

    	- 27 -

    	 	 	 

    

 

(a) resolutions of each such Person’s
board of directors (or other managing body, in the case of other than a corporation) then in full force and effect authorizing
the execution, delivery and performance of each Loan Document to be executed by such Person and the transactions contemplated hereby
and thereby; and

 

(b) the incumbency and signatures
of those of its officers, managing member or general partner, as applicable, authorized to act with respect to each Loan Document
to be executed by such Person;

 

upon which certificates the Lender may conclusively rely until
it shall have received a further certificate of the Secretary, Assistant Secretary, managing member or general partner, as applicable,
of any such Person cancelling or amending the prior certificate of such Person.

 

Section
5.1.2 Closing Date Certificate. The Lender shall have received a certificate, dated as of the Closing Date and in
form and substance satisfactory to the Lender (the “Closing Date Certificate”), duly executed and delivered
by an Authorized Officer of the Borrower, in which certificate the Borrower shall (i) provide, among other things, the pro forma
capitalization of the Borrower immediately following the consummation of the Merger Transaction and the making of the Loan on the
Closing Date and (ii) agree and acknowledge, among other things, that the statements made therein shall be deemed to be true and
correct representations and warranties of the Borrower as of such date, and, at the time such certificate is delivered, such statements
shall in fact be true and correct, and such statements shall include that all of the conditions set forth in this Section 5.1
have been satisfied as provided herein, including without limitation, Section 5.1.18 below. All documents and agreements
required to be appended to the Closing Date Certificate, if any, shall be in form and substance satisfactory to the Lender, shall
have been executed and delivered by the requisite parties, and shall be in full force and effect.

 

Section
5.1.3 Delivery of Notes. The Lender shall have received a Note for the Loan duly executed and delivered by an Authorized
Officer of the Borrower.

 

Section
5.1.4 Financial Information, Etc. The Lender shall have received,

 

(a) audited consolidated financial
statements of the Borrower and its Subsidiaries for each of the Fiscal Year ended December 31, 2014; and

 

(b) unaudited consolidated balance
sheets of the Borrower and its Subsidiaries for each Fiscal Quarter ended after December 31, 2014, together with the related consolidated
statement of operations, shareholder’s equity and cash flows for such Fiscal Quarter.

 

Section
5.1.5 Compliance Certificate, Etc. The Lender shall have received an initial Compliance Certificate, dated as of
the Closing Date, prepared on a pro forma basis as if the Merger Transaction (including the making of the Loan) was consummated
as of the last day of the calendar month preceding the Closing Date, duly executed (and with all schedules thereto duly completed)
and delivered by the chief financial or accounting Authorized Officer of the Borrower. The Compliance Certificate shall also include
a pro forma consolidated balance of the Borrower.

 

    	- 28 -

    	 	 	 

    

 

Section
5.1.6 Sources and Uses Certificate. At least three (3) Business Days prior to the Closing Date the Lender shall have
received the Sources and Uses Certificate duly executed and delivered by the chief financial or accounting Authorized Officer of
the Borrower, which certificate shall be in form and substance reasonably satisfactory to the Lender.

 

Section
5.1.7 Solvency, Etc. The Lender shall have received, a solvency certificate, substantially in the form of Exhibit
J hereto, duly executed and delivered by the chief financial or accounting Authorized Officer of the Borrower, dated as of
the Closing Date, certifying that the Loan Parties, taken as a whole, on a consolidated basis, after giving effect to the Loan
and the consummation of the Merger Transaction, are Solvent.

 

Section
5.1.8 Pledge and Security Agreement. The Lender shall have received executed counterparts of the Pledge and Security
Agreement, dated as of the date hereof, duly executed and delivered by each Loan Party, together with:

 

(a) certificates (in the case
of Capital Securities that are securities (as defined in the UCC)) evidencing all of the issued and outstanding capital Securities
owned by each Loan Party, which certificates in each case shall be accompanied by undated instruments of transfer duly executed
in blank, or, if any Capital Securities (in the case of Capital Securities that are uncertificated securities (as defined in the
UCC)), confirmation and evidence satisfactory to the Lender that the security interest therein has been transferred to and perfected
by the Lender in accordance with Articles 8 and 9 of the UCC and all laws otherwise applicable to the perfection of the pledge
of such Capital Securities;

 

(b) financing statements suitable
in form for naming each Loan Party as a debtor and the Lender as the secured party, or other similar instruments or documents to
be filed under the UCC of all jurisdictions as may be necessary or, in the opinion of the Lender, desirable to perfect the security
interests of the Lender pursuant to the Pledge and Security Agreement;

 

(c) UCC Form UCC-3 termination
statements, if any, necessary to release all Liens and other rights of any Person (i) in any collateral described in the Pledge
and Security Agreement previously granted by any Person, and (ii) securing any of the Indebtedness identified in Schedule 8.2(c),
together with such other UCC Form UCC-3 termination statements as the Lender may reasonably request from any Loan Party;

 

(d) evidence that all deposit
accounts, lockboxes, disbursement accounts, investment accounts maintained with PNC Bank, National Association or other similar
accounts of each Loan Party are Controlled Accounts;

 

(e) evidence that all such Controlled
Accounts maintained with PNC Bank, National Association are subject to one or more account control agreements, in favor of, and
satisfactory in form and substance to, the Lender; and

 

(f) subject to Section 7.8(b),
originals of all negotiable Documents (as defined in the UCC), Instruments (as defined in the UCC), Promissory Notes (as defined
in the UCC), and tangible Chattel Paper (as defined in the UCC) owned or held by any Loan Party and having a face amount (or equivalent)
in excess of $100,000.

 

    	- 29 -

    	 	 	 

    

 

Section
5.1.9 Intellectual Property Security Agreements. The Lender shall have received a Patent Security Agreement, a Copyright
Security Agreement and a Trademark Security Agreement, as applicable, each dated as of the Closing Date, duly executed and delivered
by each Loan Party that, pursuant to the Pledge and Security Agreement, is required to provide such intellectual property security
agreements to the Lender.

 

Section
5.1.10 Warrant. The Lender and the Borrower shall have executed and delivered the Warrant.

 

Section
5.1.11 Merger Agreement. The Lender shall have received execution copies of the Merger Agreement, all Ancillary Documents
and all amendments, waivers or other modifications thereto, if any, since February 2, 2015, together with a certificate of an Authorized
Officer of the Borrower certifying that the Merger Agreement and the Ancillary Documents are in full force and effect and there
have been no other amendments, waivers or other modifications thereto since February 2, 2015.

 

Section
5.1.12 Merger Transaction. The Merger Transaction shall have been consummated in accordance with the terms of the
Merger Agreement and the Ancillary Documents and all applicable laws, rules and regulations, in each case, without any amendment
or waiver that is materially adverse to the interests of the Lender.

 

Section
5.1.13 Insurance. The Lender shall have received (i) certified copies of the insurance policies (or binders in respect
thereof), from one or more insurance companies satisfactory to the Lender, evidencing coverage required to be maintained pursuant
to each Loan Document or (ii) evidence, satisfactory to it, that the Borrower has expended commercially reasonable efforts to obtain
such certified copies of the insurance policies (or binders in respect thereof) prior to the Closing Date. All such insurance policies
required pursuant to this Section shall (x) name the Lender as mortgagee (in the case of property insurance) or loss payee or additional
insured (in the case of liability insurance), as applicable, and (y) be in addition to any requirements to maintain specific types
of insurance contained in the other Loan Documents. Provided that (i) the Borrower has used its commercially reasonable efforts
prior to the closing to cause each such insurance policy to so name the Lender as a mortgagee, loss payee or additional insured,
and (ii) at least three (3) Business Days prior to the Closing Date the Borrower has identified to the Lender, in writing and in
reasonable detail, all such policies in respect of which, as of the Closing Date, the Lender has not been (or will not be) named
as a mortgagee, loss payee or additional insured, the failure of any such insurance policies to name the Lender as a mortgagee,
loss payee or additional insured shall not result in the failure of the conditions set forth in this Section 5.1.13 to be
satisfied.

 

Section
5.1.14 Certain Material Contracts. Copies of all Borrower Material Contracts and Celleration Material Contracts shall
have been made available to the Lender prior to the Closing Date upon its written request. The Lender shall have received a certificate
from an Authorized Officer of the Borrower certifying that (i) each such contract or agreement is in full force and effect as of
the Closing Date and (ii) there has been no amendment, waiver or other modification to any such contract or agreement since February
2, 2015, except, in each case, as disclosed in such certificate or Schedule 6.16(b). No such amendment, waiver or other
modification, if any, shall be materially adverse to the Lender’s interests.

 

    	- 30 -

    	 	 	 

    

 

Section
5.1.15 Opinions of Counsel. The Lender shall have received opinions, dated the Closing Date and addressed to the
Lender, from Haynes and Boone, LLP, New York counsel to each Loan Party, in form and substance satisfactory to the Lender.

 

Section
5.1.16 Closing Fees, Expenses, Etc. The Lender shall have received for its own account, all fees, costs and expenses
due and payable pursuant to (i) Section 3.9, and (ii) Section 11.3, and in the case of clause (ii), which
in the aggregate, as of the Closing Date, shall not exceed $275,000.

 

Section
5.1.17 Anti-Terrorism Laws. The Lender shall have received, as applicable, all documentation and other information
required by bank regulatory authorities under applicable “know your customer” and anti-money laundering rules and regulations,
including the U.S.A. Patriot Act.

 

Section
5.1.18 Closing Date Material Adverse Effect. The representations and warranties (other than Section 6.6 hereof)
are true and correct in all material respects, no Default (other than any Default arising pursuant to Section 9.1.2 as a result
of a breach of Section 6.6 hereof) shall have occurred and be continuing, or would occur as a result of making the Loan
on the Closing Date, and no Closing Date Material Adverse Effect shall have occurred since December 31, 2013.

 

Section
5.1.19 Intercompany Subordination Agreement. The Lender shall have received executed counterparts of the Subordination
Agreement, dated as of the date hereof, duly executed and delivered by each Loan Party and the Lender.

 

Article
VI

REPRESENTATIONS AND WARRANTIES

 

In order to induce the Lender to enter into
this Agreement and to make the Loan hereunder, each Loan Party, jointly and severally, represents and warrants to the Lender, as
of the consummation of the Merger Transaction on the Closing Date, as set forth in this Article.

 

Section
6.1 Organization, Etc. Each Loan Party is validly organized and existing and in good standing under the laws of the
jurisdiction of its incorporation or organization, is duly qualified to do business and is in good standing as a foreign entity
in each jurisdiction where the nature of its business requires such qualification, except where the failure to be in good standing
as a foreign entity in any such jurisdiction would not, individually or in the aggregate, reasonably be expected to result in a
Material Adverse Effect and has full power and authority and holds all requisite governmental licenses, permits and other approvals
to enter into and perform its Obligations under each Loan Document to which it is a party, to own and hold under lease its property
and to conduct its business substantially as currently conducted by it.

 

Section
6.2 Due Authorization, Non-Contravention, Etc. The execution, delivery and performance by each Loan Party of each
Loan Document executed or to be executed by it are in each case within such Person’s powers, have been duly authorized by
all necessary action, and do not:

 

    	- 31 -

    	 	 	 

    

 

(a) contravene (i) any Loan Party’s
Organic Documents, (ii) any court decree or order binding on or affecting any Loan Party or (iii) any law or governmental regulation
binding on or affecting any Loan Party, except, with respect to clause (iii), for such contraventions that would not, individually
or in the aggregate, reasonably be expected to result in a Material Adverse Effect; or

 

(b) result in or require (i) the
creation or imposition of, any Lien on any Loan Party’s properties (other than Permitted Liens) or (ii) a default under any
contractual restriction binding on or affecting any Loan Party, except, with respect to clause (ii), any default that would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

Section
6.3 Government Approval, Regulation, Etc. No authorization or approval or other action by, and no notice to or filing
with, any Governmental Authority or other Person (other than those that have been, or on the Closing Date will be, duly obtained
or made and which are, or on the Closing Date will be, in full force and effect) is required for the due execution, delivery or
performance by any Loan Party of any Loan Document to which it is a party, except for such approvals, actions, notices or filings
the failure of which to be obtained or made would not, individually or in the aggregate, reasonably be expected to result in a
Material Adverse Effect. Each Loan Party and its respective properties and businesses are in compliance in all material respects
with all laws, rules regulations, orders and court decrees applicable to such Persons, properties or businesses, as the case may
be.

 

Section
6.4 Validity, Etc. Each Loan Document to which any Loan Party is a party constitutes the legal, valid and binding
obligations of such Person enforceable against such Person in accordance with its respective terms (except, in any case, as such
enforceability may be limited by applicable bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights
generally and by principles of equity).

 

Section
6.5 Financial Information. The consolidated financial statements of the Loan Parties furnished to the Lender pursuant
to Section 5.1.4 and Sections 7.1(a), (b), and (c) have been prepared in accordance with GAAP consistently
applied, and present fairly the consolidated financial condition of the Persons covered thereby as at the dates thereof and the
results of their operations for the periods then ended.

 

Section
6.6 No Material Adverse Change. Other than the Merger Transaction, there has been no material adverse change in the
business, financial performance or condition, operations (including the results thereof), assets, properties or prospects of the
Loan Parties since December 31, 2013.

 

Section
6.7 Litigation, Labor Matters and Environmental Matters.

 

(a) Except as described on Schedule
6.7(a), there are no actions, suits or proceedings by or before any arbitrator or Governmental Authority pending against or,
to the knowledge of any Loan Party, threatened against or affecting, any Loan Party (i) as to which there is a reasonable likelihood
of an adverse determination and that, if adversely determined, would reasonably be expected, individually or in the aggregate,
to result in liabilities in excess of $500,000 or (ii) that would reasonably be likely to have a Material Adverse Effect.

 

    	- 32 -

    	 	 	 

    

 

(b) There are no labor controversies
pending against or, to the knowledge of any Loan Party, threatened against or affecting any Loan Party (i) that would reasonably
be expected, individually or in the aggregate, to result in liabilities in excess of $250,000 or (ii) that would reasonably be
likely to have a Material Adverse Effect.

 

(c) No Loan Party (i) has failed
to comply with any Environmental Law or to obtain, maintain or comply with any Permit under or in connection with any Environmental
Law (“Environmental Permit”), (ii) is or has been subject to any Environmental Liability, (iii) has received
notice of any Environmental Liability or (iv) knows of any basis for any Environmental Liability.

 

Section
6.8 Subsidiaries. The Borrower has no Subsidiaries, except those Subsidiaries which are identified on Schedule
6.8, or which are permitted to have been organized or acquired in accordance with Section 8.5 or Section 8.8.
As of the date hereof, all Subsidiaries identified on Schedule 6.8 are Guarantors.

 

Section
6.9 Ownership of Properties. Each Loan Party owns (i) in the case of owned real property, good and marketable
fee title to, and (ii) in the case of owned personal property, good and valid title to, or, in the case of leased real or
personal property, valid and enforceable leasehold interests (as the case may be) in, all of its properties and assets, tangible
and intangible, of any nature whatsoever, free and clear in each case of all Liens or claims, except for Permitted Liens.

 

Section
6.10 Taxes. Each Loan Party has filed all income and other tax returns and reports required by law to have been filed
by it and has paid all Taxes thereby shown to be due and owing, except any such Taxes which are being diligently contested in good
faith by appropriate proceedings and for which adequate reserves in accordance with GAAP shall have been set aside on its books.

 

Section
6.11 Pension Plans, Etc. During the twelve-consecutive-month
period prior to the Closing Date, no formal steps have been taken to terminate any Pension Plan, and no contribution failure has
occurred with respect to any Pension Plan sufficient to give rise to a Lien on any Loan Party or any ERISA Affiliate under Section
303(k) of ERISA or under Section 430(k) of the Code. No condition exists or event or transaction has occurred with respect to any
Pension Plan or Multiemployer Plan which would reasonably be expected to result in the incurrence by any Loan Party or ERISA Affiliate
of any material liability, fine or penalty. Except as disclosed in Schedule 6.11, no Loan Party has any Contingent Liability
with respect to any post-retirement benefit under a Welfare Plan.

 

Section
6.12 Accuracy of Information. None of the factual
information heretofore or contemporaneously furnished in writing to the Lender by or on behalf of any Loan Party in connection
with any Loan Document or any transaction contemplated hereby contains any untrue statement of a material fact, or omits to state
any material fact necessary to make any information not misleading.

 

    	- 33 -

    	 	 	 

    

 

Section
6.13 Regulations U and X. No Loan Party is engaged
in the business of extending credit for the purpose of buying or carrying margin stock, and no proceeds of the Loan will
be used to purchase or carry margin stock or otherwise for a purpose which violates, or would be inconsistent with, F.R.S. Board
Regulation U or Regulation X. Terms for which meanings are provided in F.R.S. Board Regulation U or Regulation X or any
regulations substituted therefor, as from time to time in effect, are used in this Section with such meanings.

 

Section
6.14 Solvency. The Loan Parties, taken as a whole,
on a consolidated basis, after giving effect to the Loan and the Merger Transaction, are Solvent.

 

Section
6.15 Intellectual Property.

 

(a) Schedule 6.15(a) sets
forth a complete and accurate list of all (i) Patents, (ii) registered and material unregistered Trademarks (including domain names)
and any pending registrations for Trademarks and (iii) any other registered Intellectual Property and (iv) any commercially significant
unregistered Intellectual Property, in each case owned or licensed by each Loan Party. For each item of Intellectual Property listed
on Schedule 6.15(a), the applicable Loan Party has, where relevant, indicated (A) the countries in each case in which such
item is patented, (B) the application numbers, (C) the registration or patent numbers, (D) with respect to the Patents, the expected
expiration date of the issued Patents, (E) the owner of such item of Intellectual Property and (F) with respect to Intellectual
Property owned by any third party, the agreement pursuant to which that Intellectual Property is licensed to any Loan Party.

 

(b) With respect to all Intellectual
Property of the Loan Parties listed on Schedule 6.15(a):

 

(i)
such Loan Party owns or has a valid license to such Intellectual Property free and clear of
any and all Liens other than Permitted Liens and all such Intellectual Property are in full force and effect, and have not expired,
lapsed or been forfeited, cancelled or abandoned; 

 

(ii) such Loan Party has taken commercially
reasonable actions to maintain and protect such Intellectual Property and there are no unpaid maintenance or renewal fees payable
by such Loan Party that are currently overdue for any of such registered Intellectual Property;

 

(iii) there is no proceeding challenging
the validity or enforceability of any such Intellectual Property, no Loan Party is involved in any such proceeding with any Person
and none of the Intellectual Property is the subject of any Other Administrative Proceeding;

 

(iv) to the knowledge of the Loan
Parties, (A) such Intellectual Property is valid, enforceable and subsisting and (B) no event has occurred, and nothing has been
done or omitted to have been done, that would effect the validity or enforceability of such Intellectual Property; and

 

    	- 34 -

    	 	 	 

    

 

(v) such Loan Party is the sole
and exclusive owner of all right, title and interest in and to, all such Intellectual Property that is owned by such Loan Party.

 

(c) To the knowledge of the Loan
Parties, no third party is committing any act of Infringement of any Intellectual Property listed on Schedule 6.15(a).

 

(d) With respect to each license
agreement listed on Schedule 6.15(a), such license agreement (i) is in full force and effect and is binding upon and enforceable
against each Loan Party party thereto and, to the knowledge of the responsible officer of the Borrower or any relevant Subsidiary,
all other parties party thereto in accordance with its terms, (ii) has not been amended or otherwise modified and (iii) has not
suffered a default thereunder. No Loan Party has taken any action that would permit any other Person party to any Material Agreement
to have, and to the knowledge of any responsible officer of any Loan Party, no such Person otherwise has, any defenses, counterclaims
or rights of setoff thereunder.

 

(e) No Loan Party has received
written notice from any third party alleging that the conduct of its business (including the development, manufacture, use, sale
or other commercialization of any Product) Infringes any Intellectual Property of that third party and, to the knowledge of each
Loan Party, the conduct of its business (including the development, manufacture, use, sale or other commercialization of any Product)
does not Infringe any Intellectual Property of any third party.

 

Section
6.16 Material Agreements. Set forth on Schedule
6.16(a) is a complete and accurate list as of the Closing Date of each Material Agreement of each Loan Party, with a reasonable
description of the parties, subject matter thereof and amendments and modifications thereto. Other than as set forth on Schedule
6.16(b), each such Material Agreement (i) is in full force and effect and is binding upon and enforceable against each Loan
Party party thereto and, to the knowledge of any responsible officer of the Borrower or any of its Subsidiaries, all other parties
thereto in accordance with its terms, and (ii) has not suffered a default thereunder. No Loan Party has taken any action that would
permit any other Person party to any Material Agreement to have, and to the knowledge of any responsible officer of the Borrower
or any of its Subsidiaries, no such Person otherwise has, any defenses, counterclaims or rights of setoff thereunder.

 

Section
6.17 Permits. Each Loan Party has all Permits, including
Environmental Permits, necessary or required for the ownership, operation and conduct of its business and the distribution of the
Products. All such Permits are validly held and there are no defaults thereunder.

 

    	- 35 -

    	 	 	 

    

 

Section
6.18 Regulatory Matters. With respect to each Product:

 

(a) Set forth on Schedule 6.18(a)
is a complete and accurate list as of the Closing Date of all material Regulatory Authorizations relating to the Loan Parties,
the conduct of their business and the Products (on a per Product basis). All such material Regulatory Authorizations are (i) legally
and beneficially owned exclusively by the Loan Parties, free and clear of all Liens other than Permitted Liens, (ii) validly registered
and on file with the applicable Governmental Authority, in material compliance with all registration, filing and maintenance requirements
(including any fee requirements) thereof, and (iii) in good standing, valid and enforceable with the applicable Governmental Authority
in all material respects. All required and material notices, registrations and listings, supplemental applications or notifications,
reports (including field alerts, medical device reports or other reports of adverse experiences) and other required and material
filings with respect to the Products have been filed with the FDA and all other applicable Governmental Authorities.

 

(b) (i) All material regulatory
filings required by any Regulatory Authority or in respect of any Regulatory Authorization or Product Authorization with respect
to any Product or any Product Development and Commercialization Activities have been made, and all such filings are complete and
correct in all material respects and have complied in all material respects with all applicable laws and regulations, (ii) all
clinical and pre-clinical trials, if any, of investigational Products have been and are being conducted by each Loan Party according
to all applicable laws and regulations in all material respects along with appropriate monitoring of clinical investigator trial
sites for their compliance, and (iii) each Loan Party has disclosed to the Lender all such material regulatory filings and all
material communications between representatives of each Loan Party and any Regulatory Authority.

 

(c) The Borrower and each other
Loan Party and the Borrower’s agents and the agents of each other Loan Party are in compliance in all material respects with
all applicable statutes, rules and regulations (including all Regulatory Authorizations and Product Authorizations) of all applicable
Governmental Authorities, including the FDA and all other Regulatory Authorities, with respect to each Product and all Product
Development and Commercialization Activities related thereto. The Borrower and each other Loan Party has and maintains in full
force and effect all the necessary and requisite Regulatory Authorizations and Product Authorizations. The Borrower and each other
Loan Party is in compliance in all material respects with all applicable registration and listing requirements set forth in the
FD&C Act or equivalent regulation of each other Governmental Authority having jurisdiction over such Person. Each Loan Party
adheres in all material respects to all applicable regulations of all Regulatory Authorities with respect to the Products and all
Product Development and Commercialization Activities related thereto.

 

(d) Neither the Borrower nor any
other Loan Party has received from any Regulatory Authority any notice of adverse findings with respect to any Product or any Product
Development and Commercialization Activities related thereto, including any FDA Form 483 inspectional observations, notices of
violations, Warning Letters, criminal proceeding notices under Section 305 of the FD&C Act, or any other similar communication
from any Regulatory Authority. There have been no seizures conducted or, to the Borrower’s knowledge, threatened by any Regulatory
Authority with respect to any Product, and no recalls, market withdrawals, field notifications, notifications of misbranding or
adulteration or safety alerts conducted, requested or, to the Borrower’s knowledge, threatened by any Regulatory Authority
with respect to any Product, and no recalls, market withdrawals, field notifications, notifications of misbranding or adulteration
or safety alerts have been conducted, requested or, to the Borrower’s knowledge, threatened by any Regulatory Authority relating
to any Products. Neither the Borrower nor any other Loan Party has received any written notification that remains unresolved from
the FDA or any other Regulatory Authority indicating any breach or violation of any applicable Product Authorization or Regulatory
Authorization, including that any of the Products is misbranded or adulterated as defined in the FD&C Act or the rules and
regulations promulgated thereunder.

 

    	- 36 -

    	 	 	 

    

 

(e) Neither the Borrower nor any
other Loan Party nor any officer, employee or agent thereof, has made an untrue statement of a material fact or fraudulent statements
to the FDA or any other Regulatory Authority, failed to disclose a material fact required to be disclosed to the FDA or any other
Regulatory Authority, or committed an act, made a statement, or failed to make a statement that, at the time such disclosure was
made (or was not made), could reasonably be expected to provide a basis for the FDA or any other Regulatory Authority to invoke
its policy respecting Fraud, Untrue Statements of Material Facts, Bribery and Illegal Gratuities, set forth in 56 Fed. Reg. 46191
(September 10, 1991) or any similar policy.

 

(f) Neither the Borrower nor any
other Loan Party has received any written notice that the FDA or any other applicable Regulatory Authority has commenced or initiated,
or, to the knowledge of the Borrower or any such Loan Party, threatened to commence or initiate, any action to withdraw any Regulatory
Authorization or Product Authorization or requested the recall of any Products or commenced or initiated or, to the knowledge of
the Borrower or any such Loan Party, threatened to commence or initiate, any action to enjoin any Product Development and Commercialization
Activities of the Borrower or any such Loan Party.

 

(g) The clinical, preclinical,
safety and other studies and tests conducted by or on behalf of or sponsored by the Borrower and each other Loan Party, or in respect
of which any Products or Product candidates under development have participated, were (and if still pending, are) being conducted
materially in accordance with standard medical and scientific research procedures and all applicable Product Authorizations. The
Borrower and each other Loan Party has operated within, and currently is in compliance in all material respects with, all applicable
laws, Product Authorizations and Regulatory Authorizations, as well as the rules and regulations of the FDA and each other Regulatory
Authority. Neither the Borrower nor any other Loan Party has received any notices or other correspondence from the FDA or any other
Regulatory Authority requiring the termination or suspension of any clinical, preclinical, safety or other studies or tests used
to support regulatory clearance of, or any Product Authorization or Regulatory Authorization for, any Product.

 

    	- 37 -

    	 	 	 

    

 

Section
6.19 Transactions with Affiliates. Except as set
forth on Schedule 6.19, neither the Borrower nor any Subsidiary has entered into, renewed, extended or been a part to, any
transaction (including the purchase, sale, lease, transfer or exchange
of property or assets of any kind or the rendering of services of any kind) with any Affiliate during the three-year period prior
to the Closing Date.

 

Section
6.20 Investment Company Act. No Loan Party is an
“investment company” or is “controlled” by an “investment company,” as such terms are defined
in, or subject to regulation under, the Investment Company Act of 1940, as amended.

 

Section
6.21 OFAC. No Loan Party or, to the knowledge of
the Borrower, any Related Party nor any of their respective directors, officers, or employees nor, to the knowledge of the Borrower,
any agents or other persons acting on behalf of any of the foregoing (a) is currently the target of any Sanctions, (b) is located,
organized or residing in any Designated Jurisdiction, (c) is or has been (within the previous five (5) years) engaged in any transaction
with, or for the benefit of, any Person who is now or was then the target of Sanctions or who is located, organized or residing
in any Designated Jurisdiction or (d) is or has ever been in violation of or subject to an investigation relating to Sanctions.
No Loan, nor the proceeds from the Loan, has been or will be used, directly or indirectly, to lend, contribute or provide
to, or has been or will be otherwise made available to fund, any activity or business in any Designated Jurisdiction or to fund
any activity or business of any Person located, organized or residing in any Designated Jurisdiction or who is the subject of any
Sanctions, or in any other manner that will result in any violation by any Person (including the Lender and its Affiliates) of
Sanctions.

 

Section
6.22 Anti-Corruption. No Loan Party or, to the knowledge
of the Borrower, any Related Party, nor any of their respective directors, officers, or employees nor, to the knowledge of the
Borrower, any agents or other persons acting on behalf of any of the foregoing, directly or indirectly, has (a) violated or is
in violation of any applicable anti-corruption law, (b) made, offered to make, promised to make or authorized the payment or giving
of, directly or indirectly, any Prohibited Payment and (c) been subject to any investigation by any Governmental Authority with
regard to any actual or alleged Prohibited Payment.

 

Section
6.23 Deposit and Disbursement Accounts. Schedule
6.23 contains a list as of the Closing Date of all banks and other financial institutions at which each Loan Party maintains
deposit accounts, lockboxes, disbursement accounts, investment accounts or other similar accounts, and such Schedule correctly
identifies the name, address and telephone number of each bank or financial institution, the name in which the account is held,
the type of account, and the complete account number therefor.

 

Section
6.24 Registration Rights. Except as set forth on
Schedule 6.24, no Loan Party has granted or agreed to grant any registration rights, including piggyback rights (other than
pursuant to the Warrant), to any Person.

 

    	- 38 -

    	 	 	 

    

 

Section
6.25 Use of Proceeds. All proceeds of the Loan have been applied as set forth in the Sources and Uses Certificate.

 

Article
VII

AFFIRMATIVE COVENANTS

 

Each Loan Party, jointly and severally, covenants and agrees
with the Lender that until the Termination Date has occurred, each Loan Party will perform the obligations set forth below.

 

Section
7.1 Financial Information, Reports, Notices, Etc. The Borrower will furnish the Lender copies of the following financial
statements, reports, notices and information:

 

(a) as soon as available and in
any event; within 45 days after the end of each Fiscal Quarter, an unaudited consolidated balance sheet of the Loan Parties as
of the end of such Fiscal Quarter, and consolidated statements of income and cash flow of the Loan Parties for such period, including
(in each case), in comparative form the figures for the corresponding Fiscal Quarter in, and year to date portion of, the immediately
preceding Fiscal Year, certified as complete and correct by the chief financial or accounting Authorized Officer of the Borrower
(subject to normal year-end audit adjustments);

 

(b) as soon as available and in
any event within 90 days after the end of each Fiscal Year, a copy of the consolidated balance sheet of the Borrower and its Subsidiaries,
and the related consolidated statements of income and cash flow of the Borrower and its Subsidiaries for such Fiscal Year, setting
forth in comparative form the figures for the immediately preceding Fiscal Year, audited (without any Impermissible Qualification)
by independent public accountants acceptable to the Lender, which shall include a calculation of the financial covenants set forth
in Section 8.4 and stating that, in performing the examination necessary to deliver the audited financial statements of
the Borrower, no knowledge was obtained of any Event of Default;

 

(c) concurrently with the delivery
of the financial information pursuant to clause (a), a Compliance Certificate, executed by the chief financial or accounting
Authorized Officer of the Borrower, (i) showing compliance with the financial covenants set forth in Section 8.4 and stating
that no Default has occurred and is continuing (or, if a Default has occurred, specifying the details of such Default and the action
that the Borrower or any of its Subsidiaries has taken or proposes to take with respect thereto) and (ii) stating that no
Subsidiary has been formed or acquired since the delivery of the last Compliance Certificate (or, if a Subsidiary has been formed
or acquired since the delivery of the last Compliance Certificate, a statement that such Subsidiary has complied with Section
7.8);

 

    	- 39 -

    	 	 	 

    

 

(d) upon the Lender’s prior
written request made prior to the end of any Fiscal Year, within 45 days after the commencement of such Fiscal Year, an annual
budget, a business plan and financial forecasts of the Borrower and its Subsidiaries for the then current Fiscal Year of the Borrower,
in form and substance as approved by the board of directors of the Borrower, which shall include a projection of income and a projected
cash flow statement for each Fiscal Quarter in such Fiscal Year and a projected balance sheet as of the end of each Fiscal Quarter
in such Fiscal Year, in each case prepared in reasonable detail, with appropriate presentation and discussion (in reasonable detail)
of the principal assumptions upon which such budgets and projections are based, which shall be accompanied by the statement of
an Authorized Officer of the Borrower to the effect that such budget and projections are based on reasonable and good faith estimates
and assumptions made by the management of the Borrower for the respective periods covered thereby;

 

(e) as soon as possible and in
any event within three (3) Business Days after the Borrower obtains knowledge of the occurrence of a Default, a statement of an
Authorized Officer of the Borrower setting forth details of such Default and the action which the Borrower has taken and proposes
to take with respect thereto;

 

(f) as soon as possible and in
any event within three (3) Business Days after the Borrower obtains knowledge of (i) the occurrence of any material adverse
development with respect to any litigation, action, proceeding or labor controversy described in Schedule 6.7(a) or (ii) the
commencement of any litigation, action, proceeding or labor controversy of the type and materiality described in Section 6.7,
notice thereof and, to the extent the Lender requests, copies of all documentation relating thereto;

 

(g) as soon as possible and in
any event within three (3) Business Days after the Borrower obtains knowledge of any return, recovery, dispute or claim related
to any Product or inventory that involves more than $100,000, written notice thereof from an Authorized Officer of the Borrower
which notice shall include any statement setting forth details of such return, recovery, dispute or claim;

 

(h) promptly upon becoming aware
of (i) the institution of any steps by any Person to terminate any Pension Plan, (ii) the failure of any Loan Party or any ERISA
Affiliate to make a required contribution to any Pension Plan if such failure is sufficient to give rise to a Lien on any Loan
Party or any ERISA Affiliate under Section 303(k) of ERISA or under Section 430(k) of the Code, (iii) the taking of any action
with respect to a Pension Plan which would reasonably be expected to result in the requirement that any such Person furnish a bond
or other security to the PBGC or such Pension Plan, or (iv) the occurrence of any event with respect to any Pension Plan which
would reasonably be expected to result in the incurrence by any Loan Party or any ERISA Affiliate of any material liability, fine
or penalty, notice thereof and copies of all documentation relating thereto, written notice thereof from an Authorized Officer
of the Borrower, which notice shall include a statement setting forth details of such events;

 

(i) promptly upon receipt thereof,
copies of all “management letters” (or equivalent) submitted to the Borrower or any of its Subsidiaries by the independent
public accountants referred to in clause (b) in connection with each audit made by such accountants; and

 

(j) such other financial and other
information as the Lender may from time to time reasonably request (including information and reports in such detail as the Lender
may request with respect to the terms of and information provided pursuant to the Compliance Certificate).

 

    	- 40 -

    	 	 	 

    

 

Section
7.2 Maintenance of Existence; Compliance with Contracts, Laws, Etc. Each Loan Party will (i) preserve and maintain
its legal existence (except as otherwise permitted by Section 8.8), (ii) perform in all material respects its obligations
under material agreements to which it is a party, and (iii) comply in all material respects with all applicable laws, rules, regulations
and orders, including (x) the FD&C Act and the PDMA and in connection with the preparation and submission to the FDA of NDAs,
and (y) the payment (before the same become delinquent) of all Taxes imposed upon such Loan Party or upon its property, except
to the extent being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance
with GAAP have been set aside on the books of such Loan Party, as applicable.

 

Section
7.3 Maintenance of Properties. Each Loan Party will, maintain, preserve, protect and keep its and their respective
properties in good repair, working order and condition (ordinary wear and tear excepted), and make necessary repairs, renewals
and replacements so that the business carried on by such Loan Party may be properly conducted at all times, unless such Loan Party
determines in good faith that the continued maintenance of such property is no longer economically desirable, necessary or useful
to the business of such Loan Party or the Disposition of such property is otherwise permitted by Section 8.8 or Section
8.9.

 

Section
7.4 Insurance. Each Loan Party will maintain:

 

(a) insurance on its property
with financially sound and reputable insurance companies against loss and damage in at least the amounts (and with only those deductibles)
customarily maintained, and against such risks as are typically insured against in the same general area, by Persons of comparable
size engaged in the same or similar business as such Loan Party; and

 

(b) all worker’s compensation,
employer’s liability insurance or similar insurance as may be required under the laws of any state or jurisdiction in which
it may be engaged in business.

 

Without limiting the foregoing, all insurance policies required
pursuant to this Section shall (i) name the Lender as mortgagee (in the case of property insurance) or loss payee or additional
insured (in the case of liability insurance), as applicable, and (ii) be in addition to any requirements to maintain specific
types of insurance contained in the other Loan Documents; provided that, so long as identified to the Lender in writing
and in reasonable detail at least three (3) Business Days prior to the Closing Date as required pursuant to Section 5.1.13,
the Borrower shall not be in breach of this Section 7.4 with respect to any insurance policies identified in such writing
so long as such insurance policies are made to comply with this Section 7.4 on or prior to the thirtieth day following the
Closing Date. Notwithstanding the foregoing, the Borrower shall (i) promptly, and in any event within five days after any cancellation
or modification of any insurance policy required pursuant to this Section, notify the Lender of such cancellation or modification
in writing and specify the details of such cancellation or modification and (ii) promptly, and in any event within thirty days
after the cancellation of an insurance policy, replace such insurance policy in accordance with this Section.

 

    	- 41 -

    	 	 	 

    

 

Section
7.5 Books and Records. Each Loan Party will keep books and records that accurately reflect in all material respects
all of its business affairs and transactions and permit the Lender or any of its respective representatives, at reasonable times
and intervals upon reasonable prior notice to the Borrower, to visit such Loan Party’s offices, to discuss such Loan Party’s
financial matters with its officers and employees, and its independent public accountants (and such Loan Party hereby authorizes
such independent public accountant to discuss such Loan Party’s financial matters with the Lender or its representatives
whether or not any representative of such Loan Party is present) and to examine (and photocopy extracts from) any of its books
and records. Each Loan Party shall pay any fees of such independent public accountant incurred in connection with the Lender’s
exercise of its rights pursuant to this Section. Notwithstanding the foregoing, the Lender may not request access to the Borrower’s
independent public accountants more than twice in any twelve month period.

 

Section
7.6 Environmental Law Covenant. Each Loan Party will (i) use and operate all of its and their businesses, facilities
and properties in material compliance with all Environmental Laws, and keep and maintain all Environmental Permits and remain in
compliance therewith, and (ii) promptly notify the Lender of, and provide the Lender with copies of all material claims, complaints,
notices or inquiries relating to, any actual or alleged non-compliance with any Environmental Laws or Environmental Permits or
any actual or alleged Environmental Liabilities. Each Loan Party will promptly resolve, remedy and mitigate any such non-compliance
or Environmental Liabilities, and shall keep the Lender informed as to the progress of same.

 

Section
7.7 Use of Proceeds. Proceeds of the Loan shall be used as set forth in the Sources and Uses Certificate.

 

Section
7.8 Future Guarantors, Security, Etc.

 

(a) Each Loan Party will execute
any documents, UCC-1 financing statements, UCC-3 termination statements, agreements and instruments, and take all further action
that may be required under applicable law, or that the Lender may reasonably request, in order to effectuate the transactions contemplated
by the Loan Documents and in order to grant, preserve, protect and perfect the validity and first priority (subject to Permitted
Liens) of the Liens created or intended to be created by the Loan Documents. The Borrower will promptly cause any Subsidiary acquired
or organized after the date hereof to execute a supplement (in form and substance reasonably satisfactory to the Lender) to this
Agreement and each other applicable Loan Document in favor of the Lender. The Borrower will promptly notify the Lender of any subsequently
acquired real property of any Loan Party and will provide the Lender with a description of such real property, the acquisition
date thereof and the purchase price therefor. In addition, from time to time, each Loan Party will, at its cost and expense, promptly
secure the Obligations by pledging or creating, or causing to be pledged or created, perfected Liens with respect to such of its
assets and properties as the Lender shall designate, it being agreed that it is the intent of the parties that the Obligations
shall at all times be secured by, among other things, substantially all the assets of the Loan Parties (including personal property
acquired subsequent to the Closing Date). Such Liens will be created under the Loan Documents in form and substance reasonably
satisfactory to the Lender, and each Loan Party shall deliver or cause to be delivered to the Lender all such instruments and documents
(including legal opinions and lien searches) as the Lender shall reasonably request to evidence compliance with this Section 7.8.

 

    	- 42 -

    	 	 	 

    

 

(b) With respect to the Collateral
described in clause (f) of Section 5.1.8, so long as the Borrower has (i) used its commercially reasonable efforts
to deliver such Collateral on or before the Closing Date, and (ii) has identified to the Lender in writing and in reasonable detail
at least two (2) Business Days prior to the Closing Date any portion of such Collateral that will not be delivered to the Lender
as of such date, then, solely with respect to that Collateral identified in writing pursuant to clause (ii) above, (x) the
Lender shall be deemed to have waived the requirement to deliver such identified Collateral as a condition to making the Loan as
required pursuant to Section 5.1.8(f), and (y) the Borrower shall have ten (10) days following the Closing Date to comply
with clause (a) above with respect to such identified Collateral. If not in such compliance on or before such tenth day, the Borrower
shall be deemed to be in Default of this Section 7.8.

 

Section
7.9 Obtaining of Permits, Etc. With respect to Products, each Loan Party shall obtain, maintain and preserve, and
take all necessary action to timely renew all Permits (including Key Permits) and accreditations which are necessary in the proper
conduct of its business.

 

Section
7.10 Product Licenses. Each Loan Party shall (i) maintain each Permit, including each Regulatory Authorization, from,
or file any notice or registration in, each jurisdiction in which such Loan Party is required to obtain any Permit or Regulatory
Authorization or to file any notice or registration, in order to sell or distribute the Products and (ii) promptly provide evidence
of same to the Lender.

 

Section
7.11 Maintenance of Regulatory Authorizations, Contracts, Intellectual Property, Etc. With respect to the Products,
each Loan Party will (i) maintain in full force and effect all material Regulatory Authorizations (including Device Clearance Applications
and Product Authorizations), contract rights, or other rights necessary for the operations of its business, (ii) notify the Lender,
promptly after learning thereof, of any product recalls, safety alerts, corrections, withdrawals, marketing suspensions, removals
or the like conducted, to be undertaken or issued by any Loan Party or its respective suppliers whether or not at the request,
demand or order of any Governmental Authority or otherwise with respect to any Product, or any basis for undertaking or issuing
any such action or item, (iii) maintain in full force and effect, and pay all costs and expenses relating to, all material Intellectual
Property owned or controlled by any Loan Party and all Material Agreements, (iv) notify the Lender, promptly after learning thereof,
of any Infringement or other violation by any Person of its Intellectual Property and aggressively pursue any such Infringement
or other violation except in any specific circumstances where both (x) such Loan Party is able to demonstrate that it is not commercially
reasonable to do so and (y) where not doing so does not materially adversely affect any Product, (v) use commercially reasonable
efforts to pursue and maintain in full force and effect legal protection for all new Intellectual Property developed or controlled
by such Loan Party and (vi) notify the Lender, promptly after learning thereof, of (x) any claim by any Person that the conduct
of such Loan Party’s business (including the development, manufacture, use, sale or other commercialization of any Product)
Infringes any Intellectual Property of such Loan Party and, if requested by the Lender, use commercially reasonable efforts to
resolve such claim, or (y) any event, circumstance, act or omission that would cause any representation or warranty contained in
Section 6.18 to be incorrect in any material respect if such representation or warranty was to be made at the time such
Loan Party learned of such event, circumstance, act or omission.

 

    	- 43 -

    	 	 	 

    

 

Section
7.12 Restriction of Amendments to Certain Documents. No Loan Party will amend or otherwise modify any provision of,
or waive any rights under, any Product Agreement or any documents relating thereto in a manner that is materially adverse to the
interests of the Lender without the consent of the Lender, such consent not to be unreasonably withheld or delayed. No Loan Party
will amend or otherwise modify, or waive any rights under, any other document, instrument or agreement if, in any case, such amendment,
modification or waiver would reasonably be expected to be materially adverse to the interests of the Lender, including, but not
limited to, the security interest of the Lender therein.

 

Section
7.13 Cash Management. Each Loan Party will:

 

(a) maintain all deposit accounts,
disbursement accounts, investment accounts (and other similar accounts) and lockboxes with a bank or financial institution that
has executed and delivered to the Lender an account control agreement, in form and substance reasonably acceptable to the Lender;
each such deposit account, disbursement account, investment account (or similar account) and lockbox (each, a “Controlled
Account”) shall be a cash collateral account, with all cash, checks and other similar items of payment in such account
securing payment of the Obligations, and each Loan Party shall have granted a Lien to the Lender over such Controlled Accounts;

 

(b) deposit promptly, and in any
event no later than two (2) Business Days after the date of receipt thereof, all cash, checks, drafts or other similar items of
payment relating to or constituting payments made in respect of any and all accounts and other rights and interests into Controlled
Accounts; and

 

(c) at any time after the occurrence
and during the continuance of an Event of Default, at the written request of the Lender, each Loan Party will cause all payments
constituting proceeds of accounts to be directed into lockbox accounts under agreements in form and substance satisfactory to the
Lender.

 

For the avoidance of doubt, and notwithstanding
anything herein to the contrary, the execution and delivery of account control agreements with respect to each Loan Party’s
deposit accounts, disbursement accounts, investment accounts (and other similar accounts) and/or lockboxes shall not be a condition
precedent to the Lender’s obligation to make the Loan on the Closing Date, except with respect to deposit accounts maintained
with PNC Bank, National Association.

 

    	- 44 -

    	 	 	 

    

 

Section
7.14 Modification of Organic Documents. No Loan Party will amend, modify or otherwise change its Organic Documents
if, in any case, such amendment or modification would be adverse to the interests of the Lender.

 

Section
7.15 Inconsistent Agreements. No Loan Party will enter into any agreement containing any provision which would (i)
be violated or breached by such Person hereunder or by the performance by such Person of any of its obligations hereunder or under
any other Loan Document, (ii) prohibit any such Person from granting to the Lender a Lien on any of its assets or (iii) create
or permit to exist or become effective any encumbrance (other than a Permitted Lien) or restriction on the ability of any Subsidiary
of the Borrower to (x) pay dividends or make other distributions to the Borrower, or pay any Indebtedness owed to the Borrower,
(y) make loans or advances to the Borrower or (z) transfer any of its assets or properties to the Borrower.

 

Article
VIII

negativE COVENANTS

 

Each Loan Party, jointly and severally, covenants and agrees
with the Lender that until the Termination Date has occurred, each Loan Party will perform or cause to be performed the obligations
set forth below.

 

Section
8.1 Business Activities. No Loan Party will engage in any business activity except those business activities engaged
in on the date of this Agreement and activities reasonably incidental thereto.

 

Section
8.2 Indebtedness. No Loan Party will create, incur, assume or permit to exist any Indebtedness, other than the following
(collectively, “Permitted Debt”):

 

(a) Indebtedness in respect of
the Obligations;

 

(b) Indebtedness pursuant to Hedging
Agreements;

 

(c) Indebtedness existing
as of the Closing Date which is identified in Schedule 8.2(c), and refinancing of such Indebtedness in a principal
amount not in excess of that which is outstanding on the Closing Date (as such amount has been reduced following the Closing
Date);

 

(d) unsecured Indebtedness in
respect of performance, surety or appeal bonds provided in the ordinary course of business in an aggregate amount at any time outstanding
not to exceed $250,000, but excluding (in each case) Indebtedness incurred through the borrowing of money or Contingent Liabilities
in respect thereof;

 

(e) Indebtedness in respect of
letters of credit securing such Loan Party’s obligations under any commercial real property lease agreement in an aggregate
amount at any time outstanding not to exceed $350,000;

 

(f) purchase money Indebtedness
and Capitalized Lease Liabilities in an aggregate amount at any time outstanding not to exceed $250,000; and

 

    	- 45 -

    	 	 	 

    

 

(g) the contingent Indebtedness
of the Borrower for Earn-Out Payments;

 

provided that, no Indebtedness otherwise permitted by
clauses (c), (f), or (g) shall be assumed, created or otherwise incurred if a Default has occurred and is
then continuing or would result therefrom.

 

Section
8.3 Liens. No Loan Party will create, incur, assume or permit to exist any Lien upon any of its property (including
Capital Securities of any Person), revenues or assets, whether now owned or hereafter acquired, except (each of the following clauses
(a) through (g), “Permitted Lien”):

 

(a) Liens securing payment of
the Obligations;

 

(b) Liens existing as of the Closing
Date and disclosed in Schedule 8.3(b) securing Indebtedness described in clause (c) of Section 8.2, and refinancings
of such Indebtedness; provided that, no such Lien shall encumber any additional property and the amount of Indebtedness
secured by such Lien is not increased from that existing on the Closing Date (as such Indebtedness may have been permanently reduced
subsequent to the Closing Date);

 

(c) Liens in favor of carriers,
warehousemen, mechanics, materialmen and landlords granted in the ordinary course of business for amounts not overdue or being
diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP shall have
been set aside on its books;

 

(d) Liens incurred or deposits
made in the ordinary course of business in connection with worker’s compensation, unemployment insurance or other forms of
governmental insurance or benefits, or to secure performance of tenders, statutory obligations, bids, leases or other similar obligations
(other than for borrowed money) entered into in the ordinary course of business or to secure obligations on surety and appeal bonds
or performance bonds;

 

(e) judgment Liens in existence
for less than 45 days after the entry thereof or with respect to which execution has been stayed or the payment of which is
covered in full (subject to a customary deductible) by insurance maintained with responsible insurance companies and which do not
otherwise result in an Event of Default under Section 9.1.6;

 

(f) easements, rights-of-way,
zoning restrictions, minor defects or irregularities in title and other similar encumbrances not interfering in any material respect
with the value or use of the property to which such Lien is attached;

 

(g) Liens for Taxes not at the
time delinquent or thereafter payable without penalty or being diligently contested in good faith by appropriate proceedings and
for which adequate reserves in accordance with GAAP shall have been set aside on its books; and

 

    	- 46 -

    	 	 	 

    

 

(h) Cash collateral in an amount
not to exceed $350,000 securing letters of credit permitted pursuant to Section 8.2(e).

 

Section
8.4 Financial Covenants.

 

(a) The Loan Parties, on a consolidated
basis, shall maintain a monthly minimum balance of $2,000,000 in unrestricted, unencumbered cash in one or more Controlled Accounts
that is free and clear of all Liens, other than Liens granted hereunder in favor of the Lender and Permitted Liens;

 

(b) With respect to each calculation
date set forth below (each a “Calculation Date”), Consolidated Total Revenue of the Borrower for the twelve
consecutive month period ended on such Calculation Date shall not be less than the amount set forth opposite such Calculation Date:

 

	Calculation Date	 	Consolidated Total Revenue	 
	March 31, 2016	 	$	16,335,000	 
	June 30, 2016	 	$	19,900,000	 
	September 30, 2016	 	$	22,250,000	 
	December 31, 2016	 	$	24,600,000	 
	March 31, 2017	 	$	27,200,000	 
	June 30, 2017	 	$	30,300,000	 
	September 30, 2017	 	$	33,800,000	 
	December 31, 2017	 	$	37,800,000	 
	March 31, 2018	 	$	40,000,000	 
	June 30, 2018	 	$	40,000,000	 
	September 30, 2018	 	$	40,000,000	 
	December 31, 2018	 	$	40,000,000	 
	March 31, 2019	 	$	40,000,000	 

 

Section
8.5 Investments. No Loan Party will purchase, make, incur, assume or permit to exist any Investment in any other
Person, except:

 

(a) Investments existing on the
Closing Date and identified in Schedule 8.5(a);

 

    	- 47 -

    	 	 	 

    

 

(b) Cash Equivalent Investments;

 

(c) Investments received in connection
with the bankruptcy or reorganization of, or settlement of delinquent accounts and disputes with, customers and suppliers, in each
case in the ordinary course of business;

 

(d) Investments consisting of
any deferred portion of the sales price received by any Loan Party in connection with any Disposition permitted under Section
8.9;

 

(e) Investments constituting (i) accounts
receivable arising, (ii) trade debt granted, or (iii) deposits made in connection with the purchase price of goods or
services, in each case in the ordinary course of business, or (iv) any security deposit in connection with real property lease
agreements not to exceed $200,000 in the aggregate; and

 

(f) Investments in another Loan
Party.

 

Section
8.6 Restricted Payments, Etc. No Loan Party will declare or make a Restricted Payment, or make any deposit for any
Restricted Payment, other than Restricted Payments made by Subsidiaries to the Borrower or to other wholly owned Subsidiaries.

 

Section
8.7 Issuance of Capital Securities. Except as set forth in Schedule 8.7, no Subsidiary of the Borrower will
issue any Capital Securities (whether for value or otherwise) to any Person other than (in the case of Subsidiaries), to the Borrower
or to other wholly owned Subsidiaries.

 

Section
8.8 Consolidation, Merger; Permitted Acquisitions, Etc. No Loan Party will liquidate or dissolve, consolidate with,
or merge into or with, any other Person, or purchase or otherwise acquire any other Person or all or substantially all of the assets
of any other Person (or any division thereof), except that, so long as no Event of Default has occurred and is continuing (or would
occur), (i) any Loan Party may liquidate or dissolve voluntarily into, and may merge with and into, any other Loan Party, (ii)
any Loan Party may from time to time acquire another Person or all or substantially all of the assets of another Person (or any
division thereof); provided that (A) such acquisition is approved by the boards of director of the Borrower, (B) the newly
acquired (or continuing or surviving) Person shall comply with Section 7.8 hereof and shall be engaged in a line of business
similar to the Borrower, (C) the aggregate consideration paid for all acquisitions pursuant to this clause (ii) (other than the
acquisition contemplated pursuant to the Merger Transaction) shall not exceed an amount equal to $20,000,000 less any amount paid
to acquire any inbound license pursuant to Section 8.16 hereof, (D) the aggregate consideration paid in cash for all such
acquisitions pursuant to this clause (ii) (other than the acquisition contemplated pursuant to the Merger Transaction) shall not
exceed an amount equal to $5,000,000, less the amount of cash used to acquire any inbound license pursuant to Section 8.16
hereof, (E) the Borrower shall, immediately prior to consummating any such transaction described above, deliver to the Lender a
pro forma Compliance Certificate that gives effect to such transaction and certifies pro forma compliance with Section 8.4,
such certificate to be executed and delivered by the chief financial or accounting Authorized Officer of the Borrower and (F) the
Borrower shall have complied with Section 7.8.

 

    	- 48 -

    	 	 	 

    

 

Section
8.9 Permitted Dispositions. No Loan Party will dispose of any of its assets (including accounts receivable and Capital
Securities) to any Person in one transaction or series of transactions unless such Disposition (i) is inventory or obsolete, damaged,
worn out or surplus property Disposed of in the ordinary course of its business, (ii) has an aggregate fair market value that,
when taken together with all other Dispositions made pursuant to this clause (ii), does not exceed $500,000, (iii) is made,
in cash, pursuant to an Earn-out Payment permitted under Section 8.2(g) or (iv) constitutes an Excluded Business Disposition.

 

Section
8.10 Modification of Certain Agreements. No Loan Party will consent to any amendment, supplement, waiver or other
modification of, or enter into any forbearance from exercising any rights with respect to the terms or provisions contained in
any (i) Organic Documents of any Loan Party, or (ii) Material Contracts (as defined in the Merger Agreement), in each case, if
the result would have an adverse effect on the rights or remedies of the Lender.

 

Section
8.11 Transactions with Affiliates. No Loan Party will enter into or cause or permit to exist any arrangement, transaction
or contract (including for the purchase, lease or exchange of property or the rendering of services) with any of its other Affiliates,
unless such arrangement, transaction or contract (i) is on fair and reasonable terms no less favorable to such Loan Party
than it could obtain in an arm’s-length transaction with a Person that is not an Affiliate and (ii) is of the kind which
would be entered into by a prudent Person in the position of such Loan Party with a Person that is not one of its Affiliates.

 

Section
8.12 Restrictive Agreements, Etc. No Loan Party will enter into any agreement prohibiting (i) the creation or assumption
of any Lien upon its properties, revenues or assets, whether now owned or hereafter acquired, (ii) the ability of such Loan Party
to amend or otherwise modify any Loan Document or (iii) the ability of any Subsidiary to make any payments, directly or indirectly,
to the Borrower, including by way of dividends, advances, repayments of loans, reimbursements of management and other intercompany
charges, expenses and accruals or other returns on investments. The foregoing prohibitions shall not apply to restrictions contained
(x) in any Loan Document, or (y) in the case of clause (i), any agreement governing any Indebtedness permitted
by clause (f) of Section 8.2 as to the assets financed with the proceeds of such Indebtedness.

 

Section
8.13 Sale and Leaseback. No Loan Party will directly or indirectly enter into any agreement or arrangement providing
for the sale or transfer by it of any property (now owned or hereafter acquired) to a Person and the subsequent lease or rental
of such property or other similar property from such Person.

 

Section
8.14 Product Sales. No Loan Party will sell or distribute Products or cause any sale or distribution where such Loan
Party is required to obtain any Permit, or to file any notice or registration in any jurisdiction prior to any such sale or distribution,
in each case, until such Loan Party has obtained such required Permit or filed such notice or registration.

 

Section
8.15 Outbound Licenses. No Loan Party will enter into or become bound by any outbound license or agreement unless
such outbound license (i) is approved by the board of directors of the Borrower, (ii) is entered into on an arm’s-length
basis on commercially reasonable terms, (iii) does not constitute a Disposition prohibited pursuant to Section 8.9, and
(iv) does not impair the Lender from fully exercising its rights under any of the Loan Documents in the event of a disposition
or liquidation of the rights, assets or property that is the subject of such license or agreement.

 

    	- 49 -

    	 	 	 

    

 

Section
8.16 Inbound Licenses. No Loan Party shall, after the date hereof, enter into or become bound by any inbound license
or agreement (other than over-the-counter software that is commercially available to the public) unless (i) no Default has occurred
and is continuing; (ii) such Loan Party has provided written notice to the Lender of the material terms of such license or agreement
with a description of its anticipated and projected impact on such Loan Party’s business or financial condition, and (iii)
such Loan Party has taken such commercially reasonable actions as the Lender may reasonably request to obtain the consent of, or
waiver by, any Person whose consent or waiver is necessary for the Lender to be granted a valid and perfected security interest
in such license or agreement allowing the Lender to fully exercise its rights under any of the Loan Documents in the event of a
disposition or liquidation of the rights, assets or property that is the subject of such license or agreement; provided
that (A) the aggregate consideration paid for all such inbound licenses pursuant to this Section 8.16 shall not exceed an
amount equal to $20,000,000 less any amount paid for any acquisition pursuant to Section 8.8 hereof, and (B) the aggregate
consideration paid in cash for all such inbound licenses pursuant to this Section 8.16 shall not exceed an amount equal
to $5,000,000, less the amount of cash used for any acquisitions pursuant to Section 8.8 hereof.

 

Section
8.17 Change in Name, Location, Executive Office, or Executive Management; Change in Fiscal Year. Unless the Borrower
has given the Lender 30 days prior written notice, no Loan Party will (i) change its legal name or any trade name used to identify
it in the conduct of its business or ownership of its properties, (ii) change its jurisdiction of organization or legal structure,
(iii) relocate its chief executive office, principal place of business or any office in which it maintains books or records relating
to its business (including the establishment of any new office or facility), (iv) change its federal taxpayer identification number
or organizational number (or equivalent) without 30 days prior written notice to the Lender, or (v) replace its chief financial
officer. No Loan Party will change its Fiscal Year or any of its Fiscal Quarters.

 

Article
IX

EVENTS OF DEFAULT

 

Section
9.1 Listing of Events of Default. Each of the following events or occurrences described in this Article shall constitute
an “Event of Default”.

 

Section
9.1.1 Non-Payment of Obligations. The Borrower shall default in the payment or prepayment when due of (i) any principal
of or interest on the Loan, or (ii) any fee described in Article III or any other monetary Obligation, and in the
case of clause (ii) such default shall continue unremedied for a period of three (3) Business Days after such amount was
due.

 

Section
9.1.2 Breach of Warranty. Any representation or warranty made or deemed to be made by any Loan Party in any Loan
Document (including any certificates delivered pursuant to Article V) is or shall be incorrect when made or deemed to have
been made in any material respect.

 

    	- 50 -

    	 	 	 

    

 

Section
9.1.3 Non-Performance of Certain Covenants and Obligations. Any Loan Party shall default in the due performance or
observance of any of its obligations under Sections 7.4, 7.7, 7.8, 7.13, or Article VIII.

 

Section
9.1.4 Non-Performance of Other Covenants and Obligations. Any Loan Party shall default in the due performance and
observance of any other covenant, obligation or agreement contained in any Loan Document executed by it, and such default shall
continue unremedied for a period of fifteen (15) days after the earlier to occur of (a) written notice thereof given to the
Borrower by the Lender or (b) the date on which any Loan Party has actual knowledge of such default.

 

Section
9.1.5 Default on Other Indebtedness. A default shall occur in the payment of any amount when due (subject to any
applicable grace period), whether by acceleration or otherwise, of any principal or stated amount of, or interest or fees on, any
Indebtedness (other than Indebtedness permitted under Section 8.2) of any Loan Party having a principal or stated amount,
individually or in the aggregate, in excess of $250,000, or a default shall occur in the performance or observance of any obligation
or condition with respect to such Indebtedness if the effect of such default is to accelerate the maturity of any such Indebtedness
or such default shall continue unremedied for any applicable period of time sufficient to permit the holder or holders of such
Indebtedness, or any trustee or agent for such holders, to cause or declare such Indebtedness to become due and payable or to require
such Indebtedness to be prepaid, redeemed, purchased or defeased, or require an offer to purchase or defease such Indebtedness
to be made, prior to its expressed maturity.

 

Section
9.1.6 Judgments. Any judgment or order for the payment of money individually or in the aggregate in excess of $500,000
(exclusive of any amounts fully covered by insurance (less any applicable deductible) and as to which the insurer has acknowledged
its responsibility to cover such judgment or order) shall be rendered against any Loan Party and such judgment shall not have been
vacated or discharged or stayed or bonded pending appeal within 45 days after the entry thereof or enforcement proceedings
shall have been commenced by any creditor upon such judgment or order.

 

Section
9.1.7 Change in Control. Any Change in Control shall occur.

 

Section
9.1.8 Bankruptcy, Insolvency, Etc. Any Loan Party shall:

 

(a) become insolvent or generally
fail to pay, or admit in writing its inability or unwillingness generally to pay, debts as they become due;

 

(b) apply for, consent to, or
acquiesce in the appointment of a trustee, receiver, sequestrator or other custodian for any substantial part of the property of
any thereof, or make a general assignment for the benefit of creditors;

 

    	- 51 -

    	 	 	 

    

 

(c) in the absence of such application,
consent or acquiescence in or permit or suffer to exist the appointment of a trustee, receiver, sequestrator or other custodian
for a substantial part of the property of any thereof, and such trustee, receiver, sequestrator or other custodian shall not be
discharged within 60 days; provided that, each Loan Party hereby expressly authorizes the Lender to appear in any court
conducting any relevant proceeding during such 60-day period to preserve, protect and defend its rights under the Loan Documents;

 

(d) permit or suffer to exist
the commencement of any bankruptcy, reorganization, debt arrangement or other case or proceeding under any bankruptcy or insolvency
law or any dissolution, winding up or liquidation proceeding, in respect thereof, and, if any such case or proceeding is not commenced
by a Loan Party, such case or proceeding shall be consented to or acquiesced in by a Loan Party, as the case may be, or shall result
in the entry of an order for relief or shall remain for 60 days undismissed; provided that, each Loan Party hereby
expressly authorizes the Lender to appear in any court conducting any such case or proceeding during such 60-day period to preserve,
protect and defend its rights under the Loan Documents; or

 

(e) take any action authorizing,
or in furtherance of, any of the foregoing.

 

Section
9.1.9 Impairment of Security, Etc. Any Loan Document or any Lien granted thereunder shall (except in accordance with
its terms), in whole or in part, terminate, cease to be effective or cease to be the legally valid, binding and enforceable obligation
of any Loan Party party thereto; any Loan Party shall, directly or indirectly, contest in any manner such effectiveness, validity,
binding nature or enforceability; or, except as permitted under any Loan Document, any Lien securing any Obligation shall, in whole
or in part, cease to be a perfected first priority Lien.

 

Section
9.1.10 Material Adverse Change. Any circumstance occurs that could reasonably be expected to have a Material Adverse
Effect.

 

Section
9.1.11 Regulatory Matters. If any of the following occurs: (i) the FDA or any other Governmental Authority (A) issues
a letter or other communication asserting any Product lacks a required Product Authorization, including in respect of CE marks
or 510(k)s, or (B) initiates enforcement action against, or issues a warning letter with respect to, any Loan Party, or any of
their Products or the manufacturing facilities therefor, that causes any Loan Party to discontinue marketing or withdraw any of
its material Products, or causes a delay in the manufacture of any of its material Products, which discontinuance, withdrawal or
delay lasts for more than 90 days, (ii) there is a recall of any Product that has generated or is expected to generate at least
$1,000,000 in revenue for the Loan Parties in the aggregate over any consecutive twelve (12) month period or (iii) any Loan Party
enters into a settlement agreement with the FDA or any other Governmental Authority that results in aggregate liability as to any
single or related series of transactions, incidents or conditions, in excess of $500,000.

 

Section
9.1.12 Pension Plans. Any of the following events shall occur with respect to any Pension Plan:

 

    	- 52 -

    	 	 	 

    

 

(a) the institution of any steps
by any Loan Party, any ERISA Affiliate or any other Person to terminate a Pension Plan if, as a result of such termination, any
Loan Party or any such ERISA Affiliate would be required to make a contribution to such Pension Plan, or would reasonably expect
to incur a liability or obligation to such Pension Plan, in excess of $250,000;

 

(b) a contribution failure occurs
with respect to any Pension Plan sufficient to give rise to a Lien on the Borrower or any ERISA Affiliate under section 303(k)
of ERISA or under Section 430(k) of the Code; or

 

(c) any ERISA Event shall occur,
which would reasonably be expected to result in a Material Adverse Effect.

 

Section
9.1.13 Celgene License Agreement. The Borrower is in default under the Celgene License Agreement; the Celgene License
Agreement is terminated or otherwise is no longer in full force and effect with respect to the Borrower; or the Celgene License
Agreement has been amended, waived or otherwise modified in a manner materially adverse to the Lender’s interests.

 

Section
9.1.14 Key Permit Events. Any Key Permit or any of the Loan Parties’ material rights or interests thereunder
is terminated, amended or otherwise determined to be ineffective in any manner adverse to any of the Products or Loan Parties in
any material respect.

 

Section
9.2 Action if Bankruptcy. If any Event of Default described in clauses (a) through (d) of Section
9.1.8 with respect to any Loan Party shall occur, the Commitments (if not theretofore terminated) shall automatically terminate
and the outstanding principal amount of the Loan and all other Obligations shall automatically be and become immediately due and
payable, without notice or demand to any Person.

 

Section
9.3 Action if Other Event of Default. If any Event of Default (other than any Event of Default described in clauses
(a) through (d) of Section 9.1.8) shall occur for any reason, whether voluntary or involuntary, and be continuing,
the Lender may, by notice to the Borrower declare all or any portion of the outstanding principal amount of the Loan and other
Obligations to be due and payable and/or the Commitments (if not theretofore terminated) to be terminated, whereupon the full unpaid
amount of the Loan and other Obligations which shall be so declared due and payable shall be and become immediately due and payable,
without further notice, demand or presentment, and the Commitments shall terminate.

 

Article
X

GUARANTY

 

Section
10.1 Guaranty. Each Guarantor hereby agrees that such Guarantor is jointly and severally liable for, and hereby absolutely
and unconditionally guarantees to the Lender and its successors and assigns, the full and prompt payment (whether at stated maturity,
by acceleration or otherwise) and performance of, all Obligations owed or hereafter owing to Lender by each Loan Party. Each Guarantor
agrees that its guaranty obligation hereunder is a continuing guaranty of payment and performance and not of collection, and that
its obligations under this Article X shall be absolute and unconditional, irrespective of, and unaffected by, 

 

    	- 53 -

    	 	 	 

    

 

(a) the genuineness, validity,
regularity, enforceability or any future amendment of, or change in, this Agreement, any other Loan Document or any other agreement,
document or instrument to which any Loan Party is or may become a party;

 

(b) the absence of any action
to enforce this Agreement (including this Article X) or any other Loan Document or the waiver or consent by the Lender with
respect to any of the provisions thereof;

 

(c) the existence, value or condition
of, or failure to perfect its Lien against, any security for the Obligations or any action, or the absence of any action, by the
Lender in respect thereof (including the release of any such security);

 

(d) the insolvency of any Loan
Party; or

 

(e) any other action or circumstances
which might otherwise constitute a legal or equitable discharge or defense of a surety or guarantor,

 

it being agreed by each Guarantor
that its obligations under this Article X shall not be discharged until the Termination Date. Each Guarantor shall be regarded,
and shall be in the same position, as principal debtor with respect to the Obligations guaranteed hereunder.

 

Section
10.2 Waivers. Each Guarantor expressly waives all rights it may have now or in the future under any statute, or at
common law, or at law or in equity, or otherwise, to compel the Lender to marshal assets or to proceed in respect of the Obligations
guaranteed hereunder against the Borrower or any other Guarantor, any other party or against any security for the payment and performance
of the Obligations before proceeding against, or as a condition to proceeding against, such Guarantor. It is agreed among each
Guarantor and the Lender that the foregoing waivers are of the essence of the transaction contemplated by this Agreement and the
other Loan Documents and that, but for the provisions of this Article X and such waivers, the Lender would decline to enter
into this Agreement.

 

Section
10.3 Benefit of Guaranty. Each Guarantor agrees that the provisions of this Article X are for the benefit
of the Lender and its successors, transferees, endorsees and assigns, and nothing herein contained shall impair, as between the
Borrower, on the one hand, and the Lender, on the other hand, the obligations of the Borrower and each Guarantor under the Loan
Documents.

 

Section
10.4 Subordination of Subrogation, Etc. Notwithstanding anything to the contrary in this Agreement or in any other
Loan Document, each Guarantor hereby expressly and irrevocably subordinates to the prior payment in full, in cash, of the Obligations
any and all rights at law or in equity to subrogation, reimbursement, exoneration, contribution, indemnification or set off and
any and all defenses available to a surety, guarantor or accommodation co-obligor until all Commitments have expired or been terminated
and the Obligations are indefeasibly paid in full in cash. Each Guarantor acknowledges and agrees that this subordination is intended
to benefit the Lender and shall not limit or otherwise affect such Guarantor’s liability hereunder or the enforceability
of this Article X, and that the Lender and its successors and assigns are intended third party beneficiaries of the waivers
and agreements set forth in this Section 10.4.

 

    	- 54 -

    	 	 	 

    

 

Section
10.5 Election of Remedies. If the Lender may, under applicable law, proceed to realize its benefits under any of
the Loan Documents giving the Lender a Lien upon any collateral, whether owned by any Loan Party or by any other Person, either
by judicial foreclosure or by non-judicial sale or enforcement, the Lender may, at its sole option, determine which of its remedies
or rights it may pursue without affecting any of its rights and remedies under this Article X. If, in the exercise of any
of its rights and remedies, the Lender shall forfeit any of its rights or remedies, including its right to enter a deficiency judgment
against any Loan Party or any other Person, whether because of any applicable laws pertaining to “election of remedies”
or the like, each Guarantor hereby consents to such action by the Lender and waives any claim based upon such action, even if such
action by the Lender shall result in a full or partial loss of any rights of subrogation which each Guarantor might otherwise have
had but for such action by the Lender. Any election of remedies which results in the denial or impairment of the right of the Lender
to seek a deficiency judgment against the any Loan Party shall not impair any Guarantor’s obligation to pay the full amount
of the Obligations. In the event the Lender shall bid at any foreclosure or trustee’s sale or at any private sale permitted
by law or the Loan Documents, the Lender may bid all or less than the amount of the Obligations and the amount of such bid need
not be paid by the Lender but shall be credited against the Obligations. The amount of the successful bid at any such sale, whether
the Lender or any other party is the successful bidder, shall be conclusively deemed to be the fair market value of the collateral
and the difference between such bid amount and the remaining balance of the Obligations shall be conclusively deemed to be the
amount of the Obligations guaranteed under this Article X, notwithstanding that any present or future law or court decision
or ruling may have the effect of reducing the amount of any deficiency claim to which the Lender might otherwise be entitled but
for such bidding at any such sale.

 

Section
10.6 Limitation. Notwithstanding any provision herein contained to the contrary, each Guarantor’s liability
under this Article X shall be limited to an amount not to exceed the amount which could be claimed by the Lender from such
Guarantor under this Article X without rendering such claim voidable or avoidable under Section 548 of Chapter 11 of the
United States Bankruptcy Code or under any applicable state Uniform Fraudulent Transfer Act, Uniform Fraudulent Conveyance Act
or similar statute or common law after taking into account, among other things, such Guarantor’s right of contribution and
indemnification from each other Guarantor.

 

Section
10.7 Liability Cumulative. The liability of each Guarantor under this Article X is in addition to and shall
be cumulative with all liabilities of each Loan Party to the Lender under this Agreement and the other Loan Documents to which
each Loan Party is a party or in respect of any Obligations or obligation of such Loan Party, without any limitation as to amount,
unless the instrument or agreement evidencing or creating such other liability specifically provides to the contrary.

 

Article
XI

MISCELLANEOUS PROVISIONS

 

Section
11.1 Waivers, Amendments, Etc. The provisions of each Loan Document may from time to time be amended, modified or
waived, if such amendment, modification or waiver is in writing and consented to by the Lender and, so long as no Event of Default
has occurred and is continuing, the Borrower.

 

    	- 55 -

    	 	 	 

    

 

No failure or delay on the part of the Lender in exercising
any power or right under any Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise of any such
power or right preclude any other or further exercise thereof or the exercise of any other power or right. No notice to or demand
on any Loan Party in any case shall entitle it to any notice or demand in similar or other circumstances. No waiver or approval
by the Lender under any Loan Document shall, except as may be otherwise stated in such waiver or approval, be applicable to subsequent
transactions. No waiver or approval hereunder shall require any similar or dissimilar waiver or approval thereafter to be granted
hereunder.

 

Section
11.2 Notices; Time. All notices and other communications provided under any Loan Document shall be in writing or
by facsimile and addressed, delivered or transmitted, if to the Borrower or the Lender, to the applicable Person at its address
or facsimile number set forth on Schedule 11.2 hereto, or at such other address or facsimile number as may be designated
by such party in a notice to the other parties. Any notice, if mailed and properly addressed with postage prepaid or if properly
addressed and sent by pre-paid courier service, shall be deemed given when received; any notice, if transmitted by facsimile, shall
be deemed given when the confirmation of transmission thereof is received by the transmitter. Unless otherwise indicated, all references
to the time of a day in a Loan Document shall refer to New York City time.

 

Section
11.3 Payment of Costs and Expenses. The Borrower agrees to pay on demand all expenses of the Lender (including the
fees and out-of-pocket expenses of Morrison & Foerster LLP, counsel to the Lender and of local counsel, if any, who may be
retained by or on behalf of the Lender) in connection with:

 

(a) the negotiation, preparation,
execution and delivery of the Commitment Letter, each Loan Document, including schedules and exhibits, and any amendments, waivers,
consents, supplements or other modifications to any Loan Document as may from time to time hereafter be required, whether or not
the transactions contemplated hereby are consummated; and

 

(b) the filing or recording of
any Loan Document (including any financing statements) and all amendments, supplements, amendment and restatements and other modifications
to any thereof, searches made following the Closing Date in jurisdictions where financing statements (or other documents evidencing
Liens in favor of the Lender) have been recorded and any and all other documents or instruments of further assurance required to
be filed or recorded by the terms of any Loan Document; and

 

(c) the preparation and review
of the form of any document or instrument relevant to any Loan Document;

 

    	- 56 -

    	 	 	 

    

 

provided that the Expense Deposit (if any) shall be applied
by the Lender from time to time for purposes of satisfying the foregoing expenses of the Borrower. Notwithstanding the foregoing,
in no event shall the Borrower be required to pay, pursuant to this Section 11.3, the Commitment Letter or otherwise, any
expenses of the Lender (including the fees and out-of-pocket expenses of Morrison & Foerster LLP, counsel to the Lender and
of local counsel, if any, who may be retained by or on behalf of the Lender) incurred on or prior to the Closing Date in excess
of $275,000 in the aggregate

 

The Borrower also agrees to reimburse the Lender upon demand
for all reasonable out-of-pocket expenses (including reasonable attorneys’ fees and legal expenses of counsel to the Lender)
incurred by the Lender in connection with (i) the negotiation of any restructuring or “work-out” with the Borrower,
whether or not consummated, of any Obligations and (ii) the enforcement of any Obligations.

 

Section
11.4 Indemnification. In consideration of the execution and delivery of this Agreement by the Lender, the Borrower
hereby indemnifies, agrees to defend, exonerates and holds the Lender and each of its officers, directors, employees and agents
(collectively, the “Indemnified Parties”) free and harmless from and against any and all actions, causes of
action, suits, losses, costs, liabilities, obligations and damages, and expenses incurred in connection therewith (irrespective
of whether any such Indemnified Party is a party to the action for which indemnification hereunder is sought), including reasonable
attorneys’ and professionals’ fees and disbursements, whether incurred in connection with actions between the parties
hereto or the parties hereto and third parties (collectively, the “Indemnified Liabilities”), incurred by the
Indemnified Parties or any of them as a result of, or arising out of, or relating to (i) the entering into and performance of any
Loan Document by any of the Indemnified Parties (including any action brought by or on behalf of the Borrower as the result of
any determination by the Lender pursuant to Article V not to fund the Loan; provided that, any such action is resolved in favor
of such Indemnified Party) or (ii) any Environmental Liability, any actual or alleged breach of or non-compliance with Environmental
Laws or Environmental Permits, any Hazardous Materials, or any other decision, act, omission or matter relating to the environment,
natural resources, health, safety or welfare. If and to the extent that the foregoing indemnification may be unenforceable for
any reason, the Borrower agrees to make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities
which is permissible under applicable law. The Lender acknowledges and agrees that in no event will the Loan Parties’ aggregate
liability under this Section 11.4 exceed the Indemnified Parties’ actual out-of-pocket pecuniary loss. In addition,
the Lender shall take commercially reasonable actions in settling or otherwise compromising any action, lawsuit or other claim
for which it may seek indemnification hereunder. This Section 11.4 shall not apply with respect to Taxes other than Taxes losses
that arise from any other non-Tax claims.

 

Section
11.5 Survival. The obligations of the Borrower under Section 4.1, Section 4.2, Section 4.3,
Section 11.3 and Section 11.4, shall in each case survive any assignment by the Lender and the occurrence of the
Termination Date. The representations and warranties made by each Loan Party in each Loan Document shall survive the execution
and delivery of such Loan Document.

 

Section
11.6 Severability. Any provision of any Loan Document which is prohibited or unenforceable in any jurisdiction shall,
as to such provision and such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating
the remaining provisions of such Loan Document or affecting the validity or enforceability of such provision in any other jurisdiction.

 

    	- 57 -

    	 	 	 

    

 

Section
11.7 Headings. The various headings of each Loan Document are inserted for convenience only and shall not affect
the meaning or interpretation of such Loan Document or any provisions thereof.

 

Section
11.8 Execution in Counterparts, Effectiveness, Etc. This Agreement may be executed by the parties hereto in several
counterparts, each of which shall be an original and all of which shall constitute together but one and the same agreement. This
Agreement shall become effective when counterparts hereof executed on behalf of the Borrower, each other Loan Party and the Lender,
shall have been received by the Lender. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g.
“pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this
Agreement.

 

Section
11.9 Governing Law; Entire Agreement. EACH LOAN DOCUMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION
(WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT
CONTEMPLATED HEREBY AND THEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK
(INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). The Loan Documents
constitute the entire understanding among the parties hereto with respect to the subject matter thereof and supersede any prior
agreements, written or oral, with respect thereto.

 

Section
11.10 Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties
hereto and their respective successors and assigns; provided that, no Loan Party may assign or transfer its rights or obligations
hereunder without the prior written consent of the Lender; and provided, further, that the Lender shall provide the
Borrower with prompt written notice of any assignment by the Lender of the Loan (in whole or in part) or any of the Lender’s
rights hereunder, unless such assignment is to an Affiliate of the Lender. Notwithstanding anything contained herein to the contrary,
in no event will the Lender (i) prior to the Closing Date, be permitted to assign or delegate any of its obligations hereunder,
including, its obligation to make the Loan subject to the terms hereof, to any Person (other than an Affiliate of the Lender) or
(ii) at any time, be permitted to assign or delegate any of its obligations hereunder, including, its obligation to make the Loan
subject to the terms hereof, to any Person engaged in the development, commercialization, sale and distribution of silver-based,
tissue-based or ultrasonic energy-based wound care products and exudate management products. The Lender, acting solely for this
purpose as a non-fiduciary agent of the Loan Parties (such agency being solely for tax purposes), shall maintain a record of each
transfer or assignment made under this Section 11.10 and shall record the names and addresses of each transferee or assign,
and principal amounts (and stated interest) of the Loan (or portion thereof) owing to, each such Person. The entries in such record
shall be conclusive absent manifest error, and each Loan Party therein shall treat each Person whose name is recorded therein as
a lender hereunder for all purposes of this Agreement. Such register shall be available for inspection by the Loan Parties at any
reasonable time and from time to time upon reasonable prior notice.

 

    	- 58 -

    	 	 	 

    

 

Section
11.11 Other Transactions. Nothing contained herein shall preclude the Lender, from engaging in any transaction, in
addition to those contemplated by the Loan Documents, with any Loan Party or any of their respective Affiliates in which such Loan
Party or such Affiliate is not restricted hereby from engaging with any other Person.

 

Section
11.12 Forum Selection and Consent to Jurisdiction. ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION
WITH, ANY LOAN DOCUMENT, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE LENDER
OR THE LOAN PARTIES IN CONNECTION HEREWITH OR THEREWITH MAY BE BROUGHT AND MAINTAINED IN THE COURTS OF THE BOROUGH OF MANHATTAN
IN THE CITY OF NEW YORK IN THE STATE OF NEW YORK OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK;
PROVIDED THAT, ANY SUIT SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT THE LENDER’S
OPTION, IN THE COURTS OF ANY JURISDICTION WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND. EACH LOAN PARTY IRREVOCABLY CONSENTS
TO THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, OR BY PERSONAL SERVICE WITHIN OR WITHOUT THE STATE OF NEW YORK
AT THE ADDRESS FOR NOTICES SPECIFIED IN SECTION 11.2. EACH LOAN PARTY HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST
EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY HAVE OR HEREAFTER MAY HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT
IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. TO THE EXTENT
THAT EACH LOAN PARTY HAS OR HEREAFTER MAY ACQUIRE ANY IMMUNITY FROM JURISDICTION OF ANY COURT OR FROM ANY LEGAL PROCESS (WHETHER
THROUGH SERVICE OR NOTICE, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID OF EXECUTION OR OTHERWISE) WITH RESPECT TO ITSELF OR
ITS PROPERTY, EACH LOAN PARTY HEREBY IRREVOCABLY WAIVES TO THE FULLEST EXTENT PERMITTED BY LAW SUCH IMMUNITY IN RESPECT OF ITS
OBLIGATIONS UNDER THE LOAN DOCUMENTS.

 

Section
11.13 Waiver of Jury Trial. THE LENDER AND EACH LOAN PARTY HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE
TO THE FULLEST EXTENT PERMITTED BY LAW ANY RIGHTS THEY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED HEREON, OR
ARISING OUT OF, UNDER, OR IN CONNECTION WITH, EACH LOAN DOCUMENT, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER
ORAL OR WRITTEN) OR ACTIONS OF THE LENDER OR EACH LOAN PARTY IN CONNECTION THEREWITH. EACH LOAN PARTY ACKNOWLEDGES AND AGREES THAT
IT HAS RECEIVED FULL AND SUFFICIENT CONSIDERATION FOR THIS PROVISION (AND EACH OTHER PROVISION OF EACH OTHER LOAN DOCUMENT TO WHICH
IT IS A PARTY) AND THAT THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE LENDER ENTERING INTO THE LOAN DOCUMENTS.

 

[SIGNATURE PAGES FOLLOW]

 

    	- 59 -

    	 	 	 

    

 

IN WITNESS WHEREOF, the parties hereto have
caused this Agreement to be executed by their respective officers thereunto duly authorized as of the day and year first above
written.

 

	 	ALLIQUA BIOMEDICAL, INC., as Borrower
	 	 	 
	 	By:	/s/ Brian M. Posner
	 	 	Name: Brian M. Posner
	 	 	Title:   Chief Financial Officer
	 	 
	 	PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP, as Lender
	 	 
	 	By:	Perceptive Credit Opportunities GP, LLC
	 	 	 
	 	By:	/s/ Joseph Edelman
	 	 	Name: Joseph Edelman
	 	 	Title:   Managing Member
	 	 
	 	AQUAMED TECHNOLOGIES, INC., as a Guarantor
	 	 	 
	 	By:	/s/ Brian M. Posner
	 	 	Name: Brian M. Posner
	 	 	Title:   Secretary
	 	 
	 	CHOICE THERAPEUTICS, INC., as a Guarantor
	 	 	 
	 	By:	/s/ Brian M. Posner
	 	 	Name: Brian M. Posner
	 	 	Title:   Secretary

  

[Signature Page to Credit Agreement]

 

    	 

    	 	 	 

    

 

	 	ALLIQUA BIOMEDICAL SUB, INC., as a Guarantor
	 	 	 
	 	By:	/s/ Brian M. Posner
	 	 	Name: Brian M. Posner
	 	 	Title:   Secretary
	 	 
	 	ALQA CEDAR, INC., as a Guarantor
	 	 	 
	 	By:	/s/ Brian M. Posner
	 	 	Name: Brian M. Posner
	 	 	Title:   Secretary

 

[Signature Page to Credit Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]